A Phase 3 interventional study of Emicizumab in Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor and Hemophilia A, sponsored by Hoffmann-La Roche. Completed at 22 sites in 10 countries. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.
Among the 22 studies testing emicizumab in Hemophilia A, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 11 in phase 3, and was the 10th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Taiwan
Ages 12+ · Men only
Chulalongkorn University · Sites in Thailand
Ages 3–30 · Men only · Healthy volunteers
Bleeding and Clotting Disorders Institute Peoria, Illinois · Sites in United States
Ages 0–90
Indiana Hemophilia &Thrombosis Center, Inc. · Sites in United States
Ages 5–45 · Men only
Versiti Blood Health · Sites in United States
Ages 0–17
By country, each count listing its studies:
emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 13 · Phase 4 6
First in 2015; this study’s year is marked. 1 started in 2020.
This study's enrollment of 73 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 27 across the 22 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
25 studies in Hemophilia A by Hoffmann-La Roche: 5 open now, 8 under way, 4 of them phase 3. Of 15 finished, 12 (80%) have results posted.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2020, is one of 12 in phase 3, and was the 17th registered.
Hoffmann-La Roche’s Hemophilia A studies by the year they started, since 2012.
2 of the studies testing emicizumab in Hemophilia A that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05181618Hoffmann-La RocheA Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis | 2026-11-19 |
| NCT05500807Bleeding and Clotting Disorders Institute Peoria, IllinoisEmicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing emicizumab in Hemophilia A, from their registry updates:
Among Hoffmann-La Roche’s 25 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in participants with mild or moderate hemophilia A without inhibitors against factor VIII (FVIII).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with mild and moderate hemophilia A without factor VIII (FVIII) inhibitors will be enrolled to receive the emicizumab loading dose regimen followed by the participant's preference of one of 3 maintenance dose regimens.
Drug: Emicizumab
Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
Also known as: Hemlibra, RO5534262, RG6013, ACE910
Model-Based Annualized Bleed Rate for Treated Bleeds
The number of treated bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Mean Calculated ABR for Treated Bleeds
The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Median Calculated ABR for Treated Bleeds
The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Model-Based ABR for All Bleeds
The number of all bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Mean Calculated ABR for All Bleeds
The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Median Calculated ABR for All Bleeds
The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Model-Based ABR for Treated Joint Bleeds
The number of treated joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Mean Calculated ABR for Treated Joint Bleeds
The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Median Calculated ABR for Treated Joint Bleeds
The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Model-Based ABR for Treated Target Joint Bleeds
The number of treated target joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Mean Calculated ABR for Treated Target Joint Bleeds
The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Median Calculated ABR for Treated Target Joint Bleeds
The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Model-Based ABR for Treated Spontaneous Bleeds
The number of treated spontaneous bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Mean Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Median Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Bleeds
The number of treated bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: Median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Bleeds
The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: Median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Bleeds
The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: Median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Model-Based ABR for All Bleeds
The number of all bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Mean Calculated ABR for All Bleeds
The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy: Median Calculated ABR for All Bleeds
The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Joint Bleeds
The number of treated joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Joint Bleeds
The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Joint Bleeds
The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Target Joint Bleeds
The number of treated target joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Target Joint Bleeds
The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Target Joint Bleeds
The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Spontaneous Bleeds
The number of treated spontaneous bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Spontaneous Bleeds
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Spontaneous Bleeds
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
CATCH Questionnaire for Adult Participants: Change From Baseline in the Daily Activity Risk Perception (RP) and Impact Domain Scores Over Time
Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the daily activity RP and impact domain has 48 items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing daily activities and higher impact of hemophilia on daily activities.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and Study completion (SC)/Early discontinuation (ED) (up to approximately 274 weeks)
CATCH Questionnaire for Adult Participants: Change From Baseline in the Social Activity RP and Impact Domain Scores Over Time
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the social activity RP and impact domain has 22 items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing social activities and higher impact of hemophilia on social activities.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Adult Participants: Change From Baseline in the Recreational Activity RP and Impact Domain Scores Over Time
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the recreational activity RP and impact domain has 32 items and a larger bank of additional items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing recreational activities and higher impact of hemophilia on recreational activities.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Adult Participants: Change From Baseline in the Work Impact (WI) and College Impact (CI) Domains Score Over Time
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, work and college impact has 10 items and the items were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated impact of hemophilia on work and college activities.
Time frame: WI: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks); CI: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Adult Participants: Change From Baseline in the Preoccupation Domain Score Over Time
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, preoccupation has 10 items which were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Adult Participants: Change From Baseline in the Treatment Burden Domain Score Over Time
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, treatment burden has 8 items which were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater perceived burden of the hemophilia treatment.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain Associated With a Bleed Over Time
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consisting of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question: "Did you get a bleed in the past 7 days?" If the response was yes, participants were asked to rate their pain by selecting the number that best described the pain associated with the bleed. Data is reported only for categories/timepoints with non-zero values.
Time frame: Baseline, Weeks 25, 49, 61, 85, 121, 133, 157 and 169 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain in Target Joints Over Time
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Do you have target joints?" (If yes, please rate your pain by picking the number that best describes your pain in your target joint(s) over the past 7 days). Data is reported only for categories/timepoints with non-zero values.
Time frame: Baseline, Weeks 1, 13, 25, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Worst Over Time
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its WORST over the past 7 days". Data is reported only for categories/timepoints with non-zero values.
Time frame: Baseline, Weeks 1, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Least Over Time
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its LEAST over the past 7 days." Data is reported only for categories/timepoints with non-zero values.
Time frame: Baseline, Weeks 1, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Least on the Average Over Time
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its average over the past 7 days". Data is reported only for categories/timepoints with non-zero values.
Time frame: Baseline, Weeks 1, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Daily Activity RP and Impact Domain Score Over Time
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, daily activity RP and impact has 38 items with each item scored on 3 or 4 points ordinal scale. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicating higher perceived risk of having a bleed while doing daily activities and higher impact of hemophilia on daily activities.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Social Activity Risk Perception and Impact Domain Score Over Time
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, social activity RP and impact has 16 items which were scored on 3 or 4 points ordinal scale. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher perceived risk of having a bleed while doing social activities and higher impact of hemophilia on social activities.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Recreational Activity RP and Impact Domain Score Over Time
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, recreational activity RP \& impact has 34 items + larger bank of additional items. The items were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher perceived risk of having a bleed while doing recreational activities and higher impact of hemophilia on recreational activities.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the School Impact Domain Score Over Time
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, school impact has 11 items and the items were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher impact of hemophilia on school activities.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Preoccupation Domain Score Over Time
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, preoccupation has 3 items which were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Treatment Burden Domain Score Over Time
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, treatment burden has 7 items which were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated lower perceived burden of the hemophilia treatment.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Pediatric Participants: Number of Participants by Responses to Their Level of Hurt Associated With a Bleed Over Time
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, pain domain (Hurt) consists of two items, assessed using an 11-point numeric rating scale where 0 = no hurt and 10 = a lot of hurt. The data reported here are from participants who answered the following question "Did you get a bleed in the past 7 days? ( If yes, how much did the bleed hurt?)." Data is reported only for categories/timepoints with non-zero values.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 85, 97, 109, 121, 133, 145 and 157
CATCH Questionnaire for Pediatric Participants: Number of Participants by Responses to Their Level of Hurt at Its Worst Over Time
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, pain domain (Hurt) consists of two items, assessed using an 11-point numeric rating scale where 0 = no hurt and 10 = a lot of hurt. The data reported here are from participants who answered the following question "What is the WORST that your body has hurt over the past 7 days". Data is reported only for categories/timepoints with non-zero values.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145,157, 169 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Caregivers: Change From Baseline in the Preoccupation Domain Score Over Time
CATCH was used to measure the effect of hemophilia and its treatment on caregivers of pediatric participants (aged \<8 years). The caregiver version has 2 domains (preoccupation and treatment burden). Of this, preoccupation has 13 items with each of the items were scored on 4 or 5 ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
CATCH Questionnaire for Caregivers: Change From Baseline in the Treatment Burden Domain Score Over Time
CATCH was used to measure the effect of hemophilia and its treatment on caregivers of pediatric participants (aged \<8 years). The caregiver version has 2 domains (preoccupation and treatment burden). Of this, treatment burden has 8 items which were scored on 4 or 5 ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater perceived burden of the hemophilia treatment.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Percentage of Participants Who Prefer Emicizumab SC Treatment, Their Previous Hemophilia IV Treatment, or Have No Preference, as Assessed Through Use of the Emicizumab Preference Survey at Week 17
The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the participant's preference for treatment with subcutaneous (SC) emicizumab, intravenous (IV) factor VIIII (FVIII), or no preference. The 95% confidence intervals were calculated using the Pearson-Clopper method.
Time frame: Week 17
Percentage of Caregivers Who Prefer Emicizumab SC Treatment, Their Child's Previous Hemophilia IV Treatment, or Have No Preference, as Assessed Through Use of the Emicizumab Preference Survey at Week 17
The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the caregiver's preference for their child's treatment with subcutaneous (SC) emicizumab, intravenous (IV) factor VIIII (FVIII), or no preference. The 95% confidence intervals were calculated using the Pearson-Clopper method.
Time frame: Week 17
Change From Baseline in Hemophilia Joint Health Scores Over Time
The HJHS measures joint health of the joints (knees, ankles, and elbows) most commonly affected by bleeding in hemophilia. The HJHS 2.1 provides joint specific total scores which are added to obtain the sum of joints totals and also a global gait score. These two scores are then added to obtain HJHS total score. The minimum score per joint is 0, the maximum score is 20. In addition, Gait is scored on a scale from 0 to 4 based on the number of skills that are not within the normal limits. The total score is the sum of scores across all six joints plus the gait score (range from 0 to 124, with 0 being normal and 124 being the most severe disease). A higher score indicates worse joint health.
Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Change From Baseline in Mean Daily Peak Activity Duration Over Time
For physical activity assessment, participants ≥5 years of age were instructed to wear the study accelerometry device on the wrist continuously (24 hours/day) every day for the designated 2-week periods during the study. A participant was considered to be compliant with the physical activity assessments if they wore the study device continuously (≥8 hours/day) every day for at least 8 days of each of the designated 2-week periods during the study. If this compliance criterion was not reached at a specific timepoint the participant was not included in the analysis of the designated 2-week periods where compliance was not reached. Daily measurements were averaged over the 14-days timepoint. Activity count was a measure of the acceleration measured by the device. The daily peak activity duration was defined as the sum of moderate to vigorous activity per day (in minutes).
Time frame: Baseline (Weeks 1-2) and Weeks 13 (Weeks 12-13 period), 25 (Weeks 24-25 period), 37 (Weeks 36-37 period), and 49 (Weeks 48-49 period)
Change From Baseline in Mean Daily Step Count Over Time
For physical activity assessment, participants ≥5 years of age were instructed to wear the study accelerometry device on the wrist continuously (24 hours/day) every day for the designated 2-week periods during the study. A participant was considered to be compliant with the physical activity assessments if they wore the study device continuously (≥8 hours/day) every day for at least 8 days of each of the designated 2-week periods during the study. If this compliance criterion was not reached at a specific timepoint the participant was not included in the analysis of the designated 2-week periods where compliance was not reached. Daily measurements were averaged over the 14-days timepoint. Activity count was a measure of the acceleration measured by the device.
Time frame: Baseline (Weeks 1-2) and Weeks 13 (Weeks 12-13), 25 (Weeks 24-25), 37 (Weeks 36-37), and 49 (Weeks 48-49)
Menstrual Bleed Questionnaire (MBQ) for Female Participants of Childbearing Potential: Change From Baseline in the MBQ Total Score Over Time
The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The MBQ score ranges from 0 to 75. Higher scores indicate a worse quality of life and more severe symptoms.
Time frame: Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 104, 109, 113, 117, 121, 125, 129, 133, 137, 141 and145
MBQ for Female Participants of Childbearing Potential: Change From Baseline in the Heaviness Subscale Score Over Time
The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for heaviness subscale ranges from 0 to 29. Higher score indicates more heavy bleeding.
Time frame: Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 89, 93, 97, 101, 104, 109, 113, 121, 125, 129, 133 and 137 (up to approximately 274 weeks)
MBQ for Female Participants of Childbearing Potential: Change From Baseline in the QoL Subscale Score Over Time
The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for QoL subscale ranges from 0 to 37. Higher scores indicate a worse QoL.
Time frame: Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 104, 109, 113, 117, 121, 125, 129, 133, 137, 141 and 145
MBQ for Female Participants of Childbearing Potential: Change From Baseline in the Irregularity Subscale Score Over Time
The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for irregularity subscale ranges from 0 to 6. Higher score indicates more irregularity.
Time frame: Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 104, 109, 113, 117, 121, 125, 129, 133, 137, 141 and 145
MBQ for Female Participants of Childbearing Potential: Change From Baseline in the Pain Subscale Score Over Time
The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for pain subscale ranges from 0 to 3. Higher score indicates severe pain.
Time frame: Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 89, 93, 97, 101, 104, 109, 113, 121, 125, 129, 133 and 137
Menstruation Diary With the Pictorial Blood Assessment Chart (PBAC) for Female Participants of Childbearing Potential: PBAC Scores Over Time
The Menstruation Diary used a PBAC, which has shown good correlation with menstrual blood loss. The PBAC is a chart that records the occurrence and size of clots, and the number of episodes of heavy bleeding (flooding), as well as depicts the amount of blood loss during a cycle.The PBAC records pad and tampon use (as either light \[1 point\], medium \[5 points\], or heavy \[10 points\] flow), clots (small \[1 point\] or large \[5 points\]), and flooding episodes (1 point each) which can be recorded as many times as necessary any day of the month. The PBAC is scored from 0 (no bleeding) onwards, with a score of \>100 defining abnormal coagulation and heavy menstrual bleeding (corresponds to \>80ml of blood loss per menstrual cycle).
Time frame: Baseline and monthly (on days of menstruation) until Study Completion (up to approximately 247 weeks)
Number of Participants With at Least One Adverse Event by Severity, According to the World Health Organization (WHO) Toxicity Grading Scale
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. As per WHO toxicity grading, Grade 1= mild, 2= moderate, 3=severe, 4=life threatening.
Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Number of Participants With Adverse Events Leading to Study Drug Discontinuation
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Number of Participants With at Least One Thromboembolic Event
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. The following signs and symptoms were recognized as potential thromboembolism (i.e., dyspnea, chest pain, leg pain, or swelling; or if in the head, headache, numbness in the face, eye pain or swelling, or vision impairment).
Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Number of Participants With at Least One Event of Thrombotic Microangiopathy
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. TMA is used to describe a group of disorders with clinical features of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage that can include the kidneys, gastrointestinal system, central nervous system, etc.
Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Number of Participants With at Least One Injection-Site Reaction by Severity, According to the WHO Toxicity Grading Scale
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Injection-site reactions are defined as AEs related that occur within 24 hours after study drug administration and are judged to be related to the study drug injection. Local injection-site reactions included erythema, hematoma, rash, discomfort, pain, and pruritus and were mostly of mild and moderate intensity. As per WHO toxicity grading, Grade 1= mild, 2= moderate, 3=severe, 4=life threatening.
Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Number of Participants With at Least One Severe Hypersensitivity, Anaphylaxis, and Anaphylactoid Event
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Number of Participants With at Least One Shifts in Clinical Laboratory Parameters From Baseline WHO Toxicity Scale Grade 0-2 to Post-baseline Grade 3 or 4
An abnormal laboratory value was defined as a laboratory test result outside of the normal range for hematology or serum chemistry parameters. The WHO toxicity grading scale, which ranges from Grades 1 to 4 (least severe to most severe, respectively; Grade 0 is within normal range), was used for assessing the severity of laboratory abnormalities and adverse events (WHO 2003). Not every laboratory abnormality qualified as an adverse event; an abnormality was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
Time frame: Up to approximately 274 weeks
Number of Participants With at Least One Adverse Events of Changes From Baseline in Vital Signs
The number of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. All of the adverse events reported here were assessed independently by the investigator as not related to treatment with emicizumab.
Time frame: Up to approximately 274 weeks
Change From Baseline in Electrocardiogram (ECG) Parameters Over Time: QT, QTcB, QTcF, RR, PR, and QRS Intervals
Time frame: Baseline, Weeks 5, 25, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181, SC/ED (up to approximately 274 weeks)
Change From Baseline in Heart Rate Over Time, as Measured by ECG
Time frame: Baseline, Weeks 5, 25, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181, SC/ED (up to approximately 274 weeks)
Plasma Trough Concentration (Ctrough) of Emicizumab Over Time
Time frame: Pre-dose at Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and 181 (up to approximately 274 weeks)
Number of Participants With Anti-Drug Antibodies Against Emicizumab at Baseline and Post-Baseline
Participants were considered to be ADA positive if they were ADA negative at baseline but develop an ADA response following study drug administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response). The sum of all visits has been reported here.
Time frame: Baseline, Weeks 5, 13, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121, 133, 145, 169, 181 and SC/ED (up to approximately 274 weeks)
Number of Participants Who Develop Anti-FVIII Inhibitors Over Time
Central laboratory measurement of anti-FVIII inhibitory antibodies (inhibitors) was performed using a Chromogenic Bethesda Assay (CBA). Participants who develop anti-FVIII inhibitors (titer ≥ 0.6 Bethesda units per milliliter \[BU/mL\]) following study drug administration were summarized.
Time frame: Up to approximately 274 weeks
A total of 73 participants with mild or moderate hemophilia A without inhibitors against Factor VIII (FVIII) took part in the study at 22 investigative sites across 10 countries from 10 February 2020 to 19 December 2025.
| Milestone | Emicizumab |
|---|---|
| Started | 73 |
| Completed 24 weeks in the study | 72 |
| Completed 52 weeks in the study | 69 |
| Treated population | 72 |
| Completed | 66 |
| Not completed | 7 |
| Withdrew: Withdrawal by subject | 7 |
The number of treated bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated bleeds per year | Emicizumab |
|---|---|
| Model-Based Annualized Bleed Rate for Treated Bleeds | 0.9 (0.55 to 1.52) |
The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated bleeds per year | Emicizumab |
|---|---|
| Mean Calculated ABR for Treated Bleeds | 0.9 (0.02 to 5.48) |
The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated bleeds per year | Emicizumab |
|---|---|
| Median Calculated ABR for Treated Bleeds | 0.0 (0.00 to 0.98) |
The number of all bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
| All bleeds per year | Emicizumab |
|---|---|
| Model-Based ABR for All Bleeds | 2.3 (1.67 to 3.12) |
The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
| All bleeds per year | Emicizumab |
|---|---|
| Mean Calculated ABR for All Bleeds | 2.3 (0.35 to 7.75) |
The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
| All bleeds per year | Emicizumab |
|---|---|
| Median Calculated ABR for All Bleeds | 1.0 (0.00 to 3.11) |
The number of treated joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated joint bleeds per year | Emicizumab |
|---|---|
| Model-Based ABR for Treated Joint Bleeds | 0.2 (0.09 to 0.57) |
The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated joint bleeds per year | Emicizumab |
|---|---|
| Mean Calculated ABR for Treated Joint Bleeds | 0.2 (0.00 to 4.15) |
The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated joint bleeds per year | Emicizumab |
|---|---|
| Median Calculated ABR for Treated Joint Bleeds | 0.0 (0.00 to 0.00) |
The number of treated target joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated target joint bleeds per year | Emicizumab |
|---|---|
| Model-Based ABR for Treated Target Joint Bleeds | 0.1 (0.03 to 0.40) |
The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated target joint bleeds per year | Emicizumab |
|---|---|
| Mean Calculated ABR for Treated Target Joint Bleeds | 0.1 (0.00 to 3.92) |
The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated target joint bleeds per year | Emicizumab |
|---|---|
| Median Calculated ABR for Treated Target Joint Bleeds | 0.0 (0.00 to 0.00) |
The number of treated spontaneous bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated spontaneous bleeds per year | Emicizumab |
|---|---|
| Model-Based ABR for Treated Spontaneous Bleeds | 0.2 (0.11 to 0.33) |
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated spontaneous bleeds per year | Emicizumab |
|---|---|
| Mean Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds | 0.3 (0.00 to 4.23) |
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated spontaneous bleeds per year | Emicizumab |
|---|---|
| Median Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds | 0.0 (0.00 to 0.00) |
The number of treated bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Bleeds | 1.0 (0.70 to 1.35) |
The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Bleeds | 1.0 (0.02 to 5.54) |
The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Bleeds | 0.4 (0.00 to 1.58) |
The number of all bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
| All bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Model-Based ABR for All Bleeds | 1.6 (1.28 to 2.09) |
The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
| All bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Mean Calculated ABR for All Bleeds | 1.6 (0.14 to 6.61) |
The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
| All bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy: Median Calculated ABR for All Bleeds | 1.1 (0.36 to 2.25) |
The number of treated joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated joint bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Joint Bleeds | 0.2 (0.14 to 0.43) |
The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated joint bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Joint Bleeds | 0.2 (0.00 to 4.19) |
The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated joint bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Joint Bleeds | 0.0 (0.00 to 0.29) |
The number of treated target joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated target joint bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Target Joint Bleeds | 0.1 (0.04 to 0.25) |
The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated target joint bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Target Joint Bleeds | 0.1 (0.00 to 3.89) |
The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated target joint bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Target Joint Bleeds | 0.0 (0.00 to 0.00) |
The number of treated spontaneous bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated spontaneous bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Spontaneous Bleeds | 0.2 (0.13 to 0.33) |
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated spontaneous bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Spontaneous Bleeds | 0.2 (0.00 to 4.11) |
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated spontaneous bleeds per year | Emicizumab |
|---|---|
| Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Spontaneous Bleeds | 0.0 (0.00 to 0.35) |
Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the daily activity RP and impact domain has 48 items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing daily activities and higher impact of hemophilia on daily activities.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 20.93 ± 20.29 |
| RP: Change at Week 13 | -2.31 ± 9.15 |
| RP: Change at Week 25 | -2.48 ± 10.34 |
| RP: Change at Week 37 | -5.05 ± 11.19 |
| RP: Change at Week 49 | -2.58 ± 13.61 |
| RP: Change at Week 61 | -3.50 ± 16.27 |
| RP: Change at Week 73 | -3.54 ± 15.99 |
| RP: Change at Week 85 | -8.32 ± 14.90 |
| RP: Change at Week 97 | -6.08 ± 13.73 |
| RP: Change at Week 109 | -5.94 ± 19.13 |
| RP: Change at Week 121 | -9.86 ± 17.18 |
| RP: Change at Week 133 | -7.26 ± 19.98 |
| RP: Change at Week 145 | -7.28 ± 14.82 |
| RP: Change at Week 157 | -8.36 ± 17.20 |
| RP: Change at Week 169 | -9.93 ± 19.96 |
| RP: Change at Week 181 | -19.16 ± NA |
| RP: Change at SC/ED | -8.22 ± 21.31 |
| Impact: Baseline | 23.56 ± 24.09 |
| Impact: Change at Week 13 | -1.73 ± 10.37 |
| Impact: Change at Week 25 | -1.83 ± 13.54 |
| Impact: Change at Week 37 | -3.10 ± 14.89 |
| Impact: Change at Week 49 | -2.80 ± 16.58 |
| Impact: Change at Week 61 | -3.27 ± 18.75 |
| Impact: Change at Week 73 | -4.29 ± 18.86 |
| Impact: Change at Week 85 | -10.82 ± 17.90 |
| Impact: Change at Week 97 | -9.20 ± 17.10 |
| Impact: Change at Week 109 | -8.33 ± 21.50 |
| Impact: Change at Week 121 | -11.14 ± 20.31 |
| Impact: Change at Week 133 | -10.64 ± 23.84 |
| Impact: Change at Week 145 | -12.33 ± 21.27 |
| Impact: Change at Week 157 | -11.54 ± 26.76 |
| Impact: Change at Week 169 | -14.32 ± 27.76 |
| Impact: Change at Week 181 | -15.63 ± NA |
| Impact: Change at SC/ED | -8.83 ± 27.56 |
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the social activity RP and impact domain has 22 items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing social activities and higher impact of hemophilia on social activities.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 22.41 ± 19.51 |
| RP: Change at Week 13 | 1.52 ± 10.44 |
| RP: Change at Week 25 | -1.05 ± 10.58 |
| RP: Change at Week 37 | -3.29 ± 12.66 |
| RP: Change at Week 49 | -2.35 ± 16.13 |
| RP: Change at Week 61 | -4.19 ± 14.27 |
| RP: Change at Week 73 | -3.38 ± 15.33 |
| RP: Change at Week 85 | -6.06 ± 16.22 |
| RP: Change at Week 97 | -5.59 ± 14.70 |
| RP: Change at Week 109 | -3.79 ± 20.29 |
| RP: Change at Week 121 | -8.62 ± 18.63 |
| RP: Change at Week 133 | -8.10 ± 21.42 |
| RP: Change at Week 145 | -7.13 ± 16.41 |
| RP: Change at Week 157 | -8.46 ± 23.94 |
| RP: Change at Week 169 | -11.39 ± 21.05 |
| RP: Change at Week 181 | -18.33 ± NA |
| RP: Change at SC/DV | -8.31 ± 22.19 |
| Impact: Baseline | 26.39 ± 24.22 |
| Impact: Change at Week 13 | -1.00 ± 12.00 |
| Impact: Change at Week 25 | -2.04 ± 12.80 |
| Impact: Change at Week 37 | -4.18 ± 16.17 |
| Impact: Change at Week 49 | -1.86 ± 17.60 |
| Impact: Change at Week 61 | -4.29 ± 19.21 |
| Impact: Change at Week 73 | -4.47 ± 19.88 |
| Impact: Change at Week 85 | -7.81 ± 18.73 |
| Impact: Change at Week 97 | -7.38 ± 18.95 |
| Impact: Change at Week 109 | -6.48 ± 24.94 |
| Impact: Change at Week 121 | -10.30 ± 22.04 |
| Impact: Change at Week 133 | -9.76 ± 25.28 |
| Impact: Change at Week 145 | -11.35 ± 22.16 |
| Impact: Change at Week 157 | -12.68 ± 32.58 |
| Impact: Change at Week 169 | -15.08 ± 31.91 |
| Impact: Change at Week 181 | -24.00 ± NA |
| Impact: Change at SC/DV | -9.33 ± 28.42 |
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the recreational activity RP and impact domain has 32 items and a larger bank of additional items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing recreational activities and higher impact of hemophilia on recreational activities.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 44.51 ± 21.91 |
| RP: Change at Week 13 | -9.29 ± 18.82 |
| RP: Change at Week 25 | -0.01 ± 23.17 |
| RP: Change at Week 37 | -8.67 ± 19.53 |
| RP: Change at Week 49 | -6.35 ± 22.51 |
| RP: Change at Week 61 | -8.47 ± 17.72 |
| RP: Change at Week 73 | -5.23 ± 25.24 |
| RP: Change at Week 85 | -6.04 ± 17.59 |
| RP: Change at Week 97 | -6.89 ± 18.49 |
| RP: Change at Week 109 | -10.14 ± 25.81 |
| RP: Change at Week 121 | -10.51 ± 24.13 |
| RP: Change at Week 133 | -14.54 ± 30.21 |
| RP: Change at Week 145 | -12.55 ± 19.01 |
| RP: Change at Week 157 | -8.89 ± 15.17 |
| RP: Change at Week 169 | -20.50 ± 40.45 |
| RP: Change at SC/DV | -13.72 ± 22.31 |
| Impact: Baseline | 40.24 ± 25.26 |
| Impact: Change at Week 13 | -5.39 ± 25.22 |
| Impact: Change at Week 25 | -1.75 ± 30.92 |
| Impact: Change at Week 37 | -6.43 ± 27.73 |
| Impact: Change at Week 49 | -2.68 ± 26.43 |
| Impact: Change at Week 61 | -1.30 ± 25.30 |
| Impact: Change at Week 73 | -4.75 ± 27.14 |
| Impact: Change at Week 85 | -12.80 ± 22.10 |
| Impact: Change at Week 97 | -8.97 ± 24.71 |
| Impact: Change at Week 109 | -9.53 ± 29.53 |
| Impact: Change at Week 121 | -11.65 ± 26.85 |
| Impact: Change at Week 133 | -10.74 ± 37.09 |
| Impact: Change at Week 145 | -0.98 ± 34.73 |
| Impact: Change at Week 157 | -3.48 ± 30.49 |
| Impact: Change at Week 169 | -38.28 ± 28.16 |
| Impact: Change at SC/DV | -16.94 ± 27.42 |
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, work and college impact has 10 items and the items were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated impact of hemophilia on work and college activities.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 30.83 ± 25.05 |
| WI: Change at Week 13 | -4.85 ± 19.98 |
| WI: Change at Week 25 | -2.32 ± 20.61 |
| WI: Change at Week 37 | -1.44 ± 22.78 |
| WI: Change at Week 49 | -2.14 ± 24.66 |
| WI: Change at Week 61 | -6.78 ± 23.88 |
| WI: Change at Week 73 | -5.02 ± 25.20 |
| WI: Change at Week 85 | -6.81 ± 21.47 |
| WI: Change at Week 97 | -6.52 ± 23.76 |
| WI: Change at Week 109 | -11.53 ± 25.63 |
| WI: Change at Week 121 | -12.54 ± 21.45 |
| WI: Change at Week 133 | -6.97 ± 28.39 |
| WI: Change at Week 145 | -16.78 ± 26.72 |
| WI: Change at Week 157 | -15.96 ± 28.49 |
| WI: Change at Week 169 | -12.63 ± 19.99 |
| WI: Change at Week 181 | -25.67 ± NA |
| WI: Change at SC/DV | -9.77 ± 18.79 |
| CI: Baseline | 4.89 ± 2.12 |
| CI: Change at Week 13 | 0 ± 0 |
| CI: Change at Week 25 | 7.33 ± 6.35 |
| CI: Change at Week 37 | 1.83 ± 7.78 |
| CI: Change at Week 49 | 1.83 ± 2.59 |
| CI: Change at Week 61 | 7.33 ± NA |
| CI: Change at Week 73 | 3.67 ± NA |
| CI: Change at Week 85 | 0 ± NA |
| CI: Change at Week 97 | 3.67 ± NA |
| CI: Change at Week 109 | -7.33 ± NA |
| CI: Change at Week 121 | -7.33 ± NA |
| CI: Change at Week 133 | 3.67 ± NA |
| CI: Change at Week 145 | -3.67 ± NA |
| CI: Change at SC/DV | -3.67 ± NA |
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, preoccupation has 10 items which were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 59.58 ± 29.11 |
| Change at Week 13 | -2.34 ± 19.68 |
| Change at Week 25 | -4.20 ± 19.11 |
| Change at Week 37 | -7.88 ± 18.73 |
| Change at Week 49 | -10.11 ± 16.33 |
| Change at Week 61 | -10.80 ± 17.75 |
| Change at Week 73 | -12.89 ± 17.00 |
| Change at Week 85 | -15.05 ± 19.07 |
| Change at Week 97 | -16.77 ± 20.20 |
| Change at Week 109 | -15.02 ± 24.08 |
| Change at Week 121 | -18.39 ± 19.88 |
| Change at Week 133 | -16.38 ± 21.17 |
| Change at Week 145 | -19.44 ± 20.48 |
| Change at Week 157 | -15.56 ± 25.83 |
| Change at Week 169 | -23.06 ± 28.39 |
| Change at Week 181 | -75.00 ± NA |
| Change at SC/DV | -16.44 ± 22.65 |
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, treatment burden has 8 items which were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater perceived burden of the hemophilia treatment.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 37.09 ± 22.81 |
| Change at Week 13 | -11.55 ± 20.91 |
| Change at Week 25 | -13.84 ± 20.86 |
| Change at Week 37 | -14.17 ± 21.16 |
| Change at Week 49 | -10.22 ± 19.82 |
| Change at Week 61 | -14.25 ± 19.53 |
| Change at Week 73 | -15.15 ± 20.78 |
| Change at Week 85 | -18.03 ± 25.79 |
| Change at Week 97 | -20.97 ± 22.19 |
| Change at Week 109 | -13.11 ± 23.03 |
| Change at Week 121 | -18.89 ± 23.64 |
| Change at Week 133 | -13.07 ± 25.96 |
| Change at Week 145 | -17.36 ± 19.09 |
| Change at Week 157 | -10.36 ± 21.06 |
| Change at Week 169 | -18.48 ± 23.21 |
| Change at Week 181 | -81.25 ± NA |
| Change at SC/ED | -16.80 ± 24.71 |
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consisting of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question: "Did you get a bleed in the past 7 days?" If the response was yes, participants were asked to rate their pain by selecting the number that best described the pain associated with the bleed. Data is reported only for categories/timepoints with non-zero values.
| Participants | Emicizumab |
|---|---|
| Baseline: Level-2 | 1 |
| Baseline: Level-7 | 2 |
| Baseline: Level-8 | 1 |
| Week 25: Level-0 | 1 |
| Week 25: Level-4 | 1 |
| Week 25: Level-8 | 1 |
| Week 49: Level-3 | 1 |
| Week 61: Level-3 | 1 |
| Week 61: Level-6 | 1 |
| Week 85: Level-6 | 1 |
| Week 85: Level-8 | 1 |
| Week 121: Level-6 | 1 |
| Week 121: Level-7 | 1 |
| Week 133: Level-4 | 2 |
| Week 133: Level-6 | 2 |
| Week 157: Level-1 | 1 |
| Week 169: Level-8 | 1 |
| SC/ED: Level-3 | 1 |
| SC/ED: Level-6 | 1 |
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Do you have target joints?" (If yes, please rate your pain by picking the number that best describes your pain in your target joint(s) over the past 7 days). Data is reported only for categories/timepoints with non-zero values.
| Participants | Emicizumab |
|---|---|
| Baseline: Level-0 | 2 |
| Baseline: Level-1 | 2 |
| Baseline: Level-2 | 2 |
| Baseline: Level-3 | 3 |
| Baseline: Level-4 | 1 |
| Baseline: Level-5 | 3 |
| Baseline: Level-6 | 3 |
| Baseline: Level-7 | 4 |
| Baseline: Level-8 | 4 |
| Baseline: Level-10 | 1 |
| Week 1: Level-7 | 1 |
| Week 13: Level-0 | 3 |
| Week 13: Level-1 | 3 |
| Week 13: Level-2 | 4 |
| Week 13: Level-3 | 5 |
| Week 13: Level-4 | 2 |
| Week 13: Level-5 | 3 |
| Week 13: Level-6 | 1 |
| Week 13: Level-7 | 1 |
| Week 13: Level-8 | 1 |
| Week 13: Level-10 | 1 |
| Week 25: Level-0 | 3 |
| Week 25: Level-1 | 1 |
| Week 25: Level-2 | 5 |
| Week 25: Level-3 | 2 |
| Week 25: Level-4 | 1 |
| Week 25: Level-5 | 5 |
| Week 25: Level-6 | 1 |
| Week 25: Level-7 | 3 |
| Week 25: Level-8 | 3 |
| Week 25: Level-9 | 1 |
| Week 37: Level-0 | 2 |
| Week 37: Level-1 | 2 |
| Week 37: Level-2 | 3 |
| Week 37: Level-3 | 1 |
| Week 37: Level-4 | 1 |
| Week 37: Level-5 | 2 |
| Week 37: Level-6 | 3 |
| Week 37: Level-7 | 4 |
| Week 37: Level-8 | 1 |
| Week 37: Level-9 | 2 |
| Week 49: Level-0 | 1 |
| Week 49: Level-1 | 2 |
| Week 49: Level-2 | 2 |
| Week 49: Level-3 | 6 |
| Week 49: Level-4 | 2 |
| Week 49: Level-5 | 1 |
| Week 49: Level-6 | 2 |
| Week 49: Level-7 | 2 |
| Week 49: Level-8 | 2 |
| Week 61: Level-1 | 5 |
| Week 61: Level-2 | 4 |
| Week 61: Level-3 | 1 |
| Week 61: Level-4 | 1 |
| Week 61: Level-5 | 2 |
| Week 61: Level-6 | 2 |
| Week 61: Level-7 | 5 |
| Week 61: Level-8 | 2 |
| Week 61: Level-9 | 1 |
| Week 73: Level-0 | 2 |
| Week 73: Level-1 | 4 |
| Week 73: Level-2 | 2 |
| Week 73: Level-3 | 2 |
| Week 73: Level-4 | 4 |
| Week 73: Level-5 | 3 |
| Week 73: Level-6 | 2 |
| Week 73: Level-7 | 3 |
| Week 73: Level-10 | 1 |
| Week 85: Level-0 | 2 |
| Week 85: Level-1 | 3 |
| Week 85: Level-2 | 4 |
| Week 85: Level-3 | 2 |
| Week 85: Level-4 | 1 |
| Week 85: Level-5 | 2 |
| Week 85: Level-6 | 3 |
| Week 85: Level-7 | 1 |
| Week 85: Level-8 | 1 |
| Week 85: Level-9 | 1 |
| Week 97: Level-0 | 3 |
| Week 97: Level-1 | 1 |
| Week 97: Level-2 | 5 |
| Week 97: Level-3 | 1 |
| Week 97: Level-4 | 1 |
| Week 97: Level-5 | 1 |
| Week 97: Level-6 | 4 |
| Week 97: Level-10 | 1 |
| Week 109: Level-0 | 2 |
| Week 109: Level-1 | 4 |
| Week 109: Level-2 | 2 |
| Week 109: Level-3 | 1 |
| Week 109: Level-4 | 3 |
| Week 109: Level-9 | 2 |
| Week 109: Level-10 | 1 |
| Week 121: Level-0 | 1 |
| Week 121: Level-1 | 1 |
| Week 121: Level-3 | 4 |
| Week 121: Level-4 | 3 |
| Week 121: Level-5 | 1 |
| Week 121: Level-6 | 2 |
| Week 121: Level-7 | 1 |
| Week 121: Level-8 | 2 |
| Week 133: Level-0 | 4 |
| Week 133: Level-1 | 2 |
| Week 133: Level-3 | 3 |
| Week 133: Level-4 | 2 |
| Week 133: Level-5 | 2 |
| Week 133: Level-6 | 2 |
| Week 133: Level-9 | 1 |
| Week 133: Level-10 | 1 |
| Week 145: Level-0 | 2 |
| Week 145: Level-2 | 2 |
| Week 145: Level-3 | 3 |
| Week 145: Level-4 | 2 |
| Week 145: Level-5 | 1 |
| Week 145: Level-6 | 1 |
| Week 145: Level-7 | 1 |
| Week 157: Level-0 | 2 |
| Week 157: Level-2 | 3 |
| Week 157: Level-4 | 1 |
| Week 157: Level-7 | 1 |
| Week 169: Level-0 | 1 |
| Week 169: Level-2 | 1 |
| Week 169: Level-3 | 3 |
| Week 169: Level-6 | 1 |
| Week 181: Level-1 | 1 |
| SC/ED: Level-0 | 1 |
| SC/ED: Level-2 | 1 |
| SC/ED: Level-3 | 1 |
| SC/ED: Level-4 | 1 |
| SC/ED: Level-5 | 4 |
| SC/ED: Level-6 | 2 |
| SC/ED: Level-7 | 2 |
| SC/ED: Level-8 | 2 |
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its WORST over the past 7 days". Data is reported only for categories/timepoints with non-zero values.
| Participants | Emicizumab |
|---|---|
| Baseline: Level-0 | 8 |
| Baseline: Level-1 | 3 |
| Baseline: Level-2 | 5 |
| Baseline: Level-3 | 5 |
| Baseline: Level-4 | 2 |
| Baseline: Level-5 | 4 |
| Baseline: Level-6 | 4 |
| Baseline: Level-7 | 2 |
| Baseline: Level-8 | 3 |
| Baseline: Level-9 | 4 |
| Week 1: Level-3 | 1 |
| Week 1: Level-9 | 1 |
| Week 13: Level-0 | 8 |
| Week 13: Level-1 | 6 |
| Week 13: Level-2 | 6 |
| Week 13: Level-3 | 4 |
| Week 13: Level-4 | 4 |
| Week 13: Level-5 | 4 |
| Week 13: Level-6 | 1 |
| Week 13: Level-7 | 1 |
| Week 13: Level-8 | 5 |
| Week 13: Level-9 | 1 |
| Week 25: Level-0 | 7 |
| Week 25: Level-1 | 3 |
| Week 25: Level-2 | 8 |
| Week 25: Level-3 | 5 |
| Week 25: Level-4 | 1 |
| Week 25: Level-5 | 5 |
| Week 25: Level-6 | 3 |
| Week 25: Level-7 | 2 |
| Week 25: Level-8 | 3 |
| Week 25: Level-9 | 4 |
| Week 37: Level-0 | 9 |
| Week 37: Level-1 | 6 |
| Week 37: Level-2 | 3 |
| Week 37: Level-3 | 3 |
| Week 37: Level-5 | 4 |
| Week 37: Level-6 | 3 |
| Week 37: Level-7 | 1 |
| Week 37: Level-8 | 4 |
| Week 37: Level-9 | 4 |
| Week 37: Level-10 | 2 |
| Week 49: Level-0 | 8 |
| Week 49: Level-1 | 5 |
| Week 49: Level-2 | 2 |
| Week 49: Level-3 | 8 |
| Week 49: Level-4 | 4 |
| Week 49: Level-5 | 4 |
| Week 49: Level-7 | 2 |
| Week 49: Level-8 | 1 |
| Week 49: Level-9 | 2 |
| Week 49: Level-10 | 2 |
| Week 61: Level-0 | 4 |
| Week 61: Level-1 | 6 |
| Week 61: Level-2 | 10 |
| Week 61: Level-3 | 1 |
| Week 61: Level-4 | 3 |
| Week 61: Level-5 | 2 |
| Week 61: Level-6 | 1 |
| Week 61: Level-7 | 3 |
| Week 61: Level-8 | 3 |
| Week 61: Level-9 | 4 |
| Week 61: Level-10 | 1 |
| Week 73: Level-0 | 6 |
| Week 73: Level-1 | 6 |
| Week 73: Level-2 | 5 |
| Week 73: Level-3 | 4 |
| Week 73: Level-4 | 2 |
| Week 73: Level-5 | 1 |
| Week 73: Level-7 | 6 |
| Week 73: Level-8 | 2 |
| Week 73: Level-9 | 3 |
| Week 73: Level-10 | 2 |
| Week 85: Level-0 | 5 |
| Week 85: Level-1 | 5 |
| Week 85: Level-2 | 5 |
| Week 85: Level-3 | 2 |
| Week 85: Level-4 | 2 |
| Week 85: Level-5 | 2 |
| Week 85: Level-6 | 1 |
| Week 85: Level-7 | 3 |
| Week 85: Level-8 | 5 |
| Week 85: Level-9 | 3 |
| Week 97: Level-0 | 6 |
| Week 97: Level-1 | 2 |
| Week 97: Level-2 | 5 |
| Week 97: Level-3 | 6 |
| Week 97: Level-4 | 2 |
| Week 97: Level-5 | 2 |
| Week 97: Level-7 | 4 |
| Week 97: Level-8 | 2 |
| Week 109: Level-0 | 5 |
| Week 109: Level-1 | 4 |
| Week 109: Level-2 | 2 |
| Week 109: Level-3 | 5 |
| Week 109: Level-4 | 1 |
| Week 109: Level-5 | 3 |
| Week 109: Level-6 | 3 |
| Week 109: Level-7 | 1 |
| Week 109: Level-8 | 2 |
| Week 109: Level-9 | 1 |
| Week 109: Level-10 | 2 |
| Week 121: Level-0 | 6 |
| Week 121: Level-1 | 2 |
| Week 121: Level-2 | 1 |
| Week 121: Level-3 | 5 |
| Week 121: Level-4 | 3 |
| Week 121: Level-5 | 4 |
| Week 121: Level-6 | 3 |
| Week 121: Level-7 | 1 |
| Week 121: Level-8 | 4 |
| Week 121: Level-9 | 1 |
| Week 121: Level-10 | 1 |
| Week 133: Level-0 | 7 |
| Week 133: Level-1 | 4 |
| Week 133: Level-2 | 2 |
| Week 133: Level-3 | 5 |
| Week 133: Level-4 | 2 |
| Week 133: Level-5 | 2 |
| Week 133: Level-6 | 2 |
| Week 133: Level-7 | 3 |
| Week 133: Level-8 | 1 |
| Week 133: Level-9 | 1 |
| Week 133: Level-10 | 2 |
| Week 145: Level-0 | 2 |
| Week 145: Level-1 | 3 |
| Week 145: Level-2 | 2 |
| Week 145: Level-3 | 3 |
| Week 145: Level-4 | 3 |
| Week 145: Level-5 | 2 |
| Week 145: Level-8 | 2 |
| Week 145: Level-9 | 1 |
| Week 145: Level-10 | 1 |
| Week 157: Level-0 | 3 |
| Week 157: Level-2 | 1 |
| Week 157: Level-3 | 2 |
| Week 157: Level-4 | 2 |
| Week 157: Level-5 | 1 |
| Week 157: Level-9 | 1 |
| Week 169: Level-0 | 1 |
| Week 169: Level-1 | 1 |
| Week 169: Level-2 | 2 |
| Week 169: Level-3 | 1 |
| Week 169: Level-4 | 3 |
| Week 169: Level-6 | 1 |
| Week 169: Level-9 | 1 |
| Week 181: Level-1 | 1 |
| SC/ED: Level-0 | 8 |
| SC/ED: Level-1 | 3 |
| SC/ED: Level-2 | 2 |
| SC/ED: Level-3 | 1 |
| SC/ED: Level-5 | 4 |
| SC/ED: Level-6 | 2 |
| SC/ED: Level-7 | 1 |
| SC/ED: Level-8 | 2 |
| SC/ED: Level-9 | 2 |
| SC/ED: Level-10 | 1 |
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its LEAST over the past 7 days." Data is reported only for categories/timepoints with non-zero values.
| Participants | Emicizumab |
|---|---|
| Baseline: Level-0 | 13 |
| Baseline: Level-1 | 7 |
| Baseline: Level-2 | 7 |
| Baseline: Level-3 | 5 |
| Baseline: Level-4 | 4 |
| Baseline: Level-5 | 1 |
| Baseline: Level-6 | 1 |
| Baseline: Level-7 | 1 |
| Baseline: Level-9 | 1 |
| Week 1: Level-2 | 1 |
| Week 1: Level-3 | 1 |
| Week 13: Level-0 | 15 |
| Week 13: Level-1 | 11 |
| Week 13: Level-2 | 3 |
| Week 13: Level-3 | 2 |
| Week 13: Level-4 | 5 |
| Week 13: Level-5 | 3 |
| Week 13: Level-6 | 1 |
| Week 25: Level-0 | 20 |
| Week 25: Level-1 | 5 |
| Week 25: Level-2 | 6 |
| Week 25: Level-3 | 3 |
| Week 25: Level-4 | 3 |
| Week 25: Level-5 | 2 |
| Week 25: Level-6 | 2 |
| Week 37: Level-0 | 16 |
| Week 37: Level-1 | 6 |
| Week 37: Level-2 | 6 |
| Week 37: Level-3 | 3 |
| Week 37: Level-4 | 2 |
| Week 37: Level-5 | 3 |
| Week 37: Level-6 | 2 |
| Week 37: Level-8 | 1 |
| Week 49: Level-0 | 15 |
| Week 49: Level-1 | 7 |
| Week 49: Level-2 | 2 |
| Week 49: Level-3 | 9 |
| Week 49: Level-4 | 3 |
| Week 49: Level-6 | 1 |
| Week 49: Level-7 | 1 |
| Week 61: Level-0 | 15 |
| Week 61: Level-1 | 8 |
| Week 61: Level-2 | 1 |
| Week 61: Level-3 | 4 |
| Week 61: Level-4 | 2 |
| Week 61: Level-5 | 4 |
| Week 61: Level-6 | 2 |
| Week 61: Level-7 | 2 |
| Week 73: Level-0 | 15 |
| Week 73: Level-1 | 10 |
| Week 73: Level-2 | 4 |
| Week 73: Level-3 | 2 |
| Week 73: Level-4 | 1 |
| Week 73: Level-5 | 5 |
| Week 85: Level-0 | 12 |
| Week 85: Level-1 | 8 |
| Week 85: Level-2 | 5 |
| Week 85: Level-3 | 1 |
| Week 85: Level-4 | 3 |
| Week 85: Level-5 | 3 |
| Week 85: Level-8 | 1 |
| Week 97: Level-0 | 14 |
| Week 97: Level-1 | 3 |
| Week 97: Level-2 | 6 |
| Week 97: Level-3 | 2 |
| Week 97: Level-4 | 2 |
| Week 97: Level-5 | 1 |
| Week 97: Level-7 | 1 |
| Week 109: Level-0 | 12 |
| Week 109: Level-1 | 5 |
| Week 109: Level-2 | 4 |
| Week 109: Level-3 | 5 |
| Week 109: Level-5 | 1 |
| Week 109: Level-6 | 1 |
| Week 109: Level-10 | 1 |
| Week 121: Level-0 | 11 |
| Week 121: Level-1 | 5 |
| Week 121: Level-2 | 6 |
| Week 121: Level-3 | 3 |
| Week 121: Level-4 | 3 |
| Week 121: Level-5 | 1 |
| Week 121: Level-6 | 1 |
| Week 121: Level-7 | 1 |
| Week 133: Level-0 | 11 |
| Week 133: Level-1 | 6 |
| Week 133: Level-2 | 3 |
| Week 133: Level-3 | 4 |
| Week 133: Level-4 | 3 |
| Week 133: Level-5 | 1 |
| Week 133: Level-6 | 2 |
| Week 133: Level-7 | 1 |
| Week 145: Level-0 | 5 |
| Week 145: Level-1 | 6 |
| Week 145: Level-2 | 4 |
| Week 145: Level-3 | 1 |
| Week 145: Level-4 | 1 |
| Week 145: Level-5 | 1 |
| Week 145: Level-6 | 1 |
| Week 157: Level-0 | 3 |
| Week 157: Level-1 | 1 |
| Week 157: Level-2 | 4 |
| Week 157: Level-4 | 1 |
| Week 157: Level-5 | 1 |
| Week 169: Level-0 | 4 |
| Week 169: Level-1 | 2 |
| Week 169: Level-2 | 3 |
| Week 169: Level-3 | 1 |
| Week 181: Level-2 | 1 |
| SC/ED: Level-0 | 8 |
| SC/ED: Level-1 | 4 |
| SC/ED: Level-2 | 6 |
| SC/ED: Level-3 | 2 |
| SC/ED: Level-4 | 1 |
| SC/ED: Level-5 | 4 |
| SC/ED: Level-7 | 1 |
CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its average over the past 7 days". Data is reported only for categories/timepoints with non-zero values.
| Participants | Emicizumab |
|---|---|
| Baseline: Level-0 | 9 |
| Baseline: Level-1 | 4 |
| Baseline: Level-2 | 4 |
| Baseline: Level-3 | 7 |
| Baseline: Level-4 | 5 |
| Baseline: Level-5 | 1 |
| Baseline: Level-6 | 5 |
| Baseline: Level-7 | 4 |
| Baseline: Level-8 | 1 |
| Week 1: Level-3 | 1 |
| Week 1: Level-6 | 1 |
| Week 13: Level-0 | 9 |
| Week 13: Level-1 | 9 |
| Week 13: Level-2 | 6 |
| Week 13: Level-3 | 5 |
| Week 13: Level-4 | 1 |
| Week 13: Level-5 | 5 |
| Week 13: Level-6 | 1 |
| Week 13: Level-7 | 3 |
| Week 13: Level-8 | 1 |
| Week 25: Level-0 | 10 |
| Week 25: Level-1 | 10 |
| Week 25: Level-2 | 5 |
| Week 25: Level-3 | 2 |
| Week 25: Level-4 | 7 |
| Week 25: Level-6 | 3 |
| Week 25: Level-7 | 2 |
| Week 25: Level-8 | 2 |
| Week 37: Level-0 | 9 |
| Week 37: Level-1 | 7 |
| Week 37: Level-2 | 5 |
| Week 37: Level-3 | 3 |
| Week 37: Level-4 | 3 |
| Week 37: Level-5 | 2 |
| Week 37: Level-6 | 6 |
| Week 37: Level-7 | 3 |
| Week 37: Level-8 | 1 |
| Week 49: Level-0 | 9 |
| Week 49: Level-1 | 7 |
| Week 49: Level-2 | 3 |
| Week 49: Level-3 | 8 |
| Week 49: Level-4 | 5 |
| Week 49: Level-5 | 1 |
| Week 49: Level-6 | 2 |
| Week 49: Level-7 | 3 |
| Week 61: Level-0 | 7 |
| Week 61: Level-1 | 10 |
| Week 61: Level-2 | 5 |
| Week 61: Level-3 | 3 |
| Week 61: Level-4 | 1 |
| Week 61: Level-5 | 3 |
| Week 61: Level-6 | 5 |
| Week 61: Level-7 | 2 |
| Week 61: Level-8 | 2 |
| Week 73: Level-0 | 8 |
| Week 73: Level-1 | 9 |
| Week 73: Level-2 | 5 |
| Week 73: Level-3 | 2 |
| Week 73: Level-4 | 3 |
| Week 73: Level-5 | 5 |
| Week 73: Level-6 | 2 |
| Week 73: Level-7 | 2 |
| Week 73: Level-9 | 1 |
| Week 85: Level-0 | 7 |
| Week 85: Level-1 | 6 |
| Week 85: Level-2 | 4 |
| Week 85: Level-3 | 3 |
| Week 85: Level-4 | 3 |
| Week 85: Level-5 | 5 |
| Week 85: Level-6 | 3 |
| Week 85: Level-7 | 1 |
| Week 85: Level-8 | 1 |
| Week 97: Level-0 | 8 |
| Week 97: Level-1 | 6 |
| Week 97: Level-2 | 5 |
| Week 97: Level-3 | 3 |
| Week 97: Level-5 | 5 |
| Week 97: Level-6 | 2 |
| Week 109: Level-0 | 4 |
| Week 109: Level-1 | 9 |
| Week 109: Level-2 | 4 |
| Week 109: Level-3 | 5 |
| Week 109: Level-4 | 3 |
| Week 109: Level-6 | 1 |
| Week 109: Level-7 | 2 |
| Week 109: Level-9 | 1 |
| Week 121: Level-0 | 6 |
| Week 121: Level-1 | 5 |
| Week 121: Level-2 | 3 |
| Week 121: Level-3 | 4 |
| Week 121: Level-4 | 5 |
| Week 121: Level-5 | 5 |
| Week 121: Level-6 | 2 |
| Week 121: Level-7 | 1 |
| Week 133: Level-0 | 8 |
| Week 133: Level-1 | 6 |
| Week 133: Level-2 | 5 |
| Week 133: Level-3 | 2 |
| Week 133: Level-4 | 3 |
| Week 133: Level-5 | 2 |
| Week 133: Level-6 | 2 |
| Week 133: Level-7 | 1 |
| Week 133: Level-8 | 1 |
| Week 133: Level-9 | 1 |
| Week 145: Level-0 | 2 |
| Week 145: Level-1 | 4 |
| Week 145: Level-2 | 4 |
| Week 145: Level-3 | 2 |
| Week 145: Level-4 | 1 |
| Week 145: Level-5 | 3 |
| Week 145: Level-6 | 2 |
| Week 145: Level-7 | 1 |
| Week 157: Level-0 | 3 |
| Week 157: Level-1 | 1 |
| Week 157: Level-2 | 2 |
| Week 157: Level-3 | 2 |
| Week 157: Level-4 | 1 |
| Week 157: Level-7 | 1 |
| Week 169: Level-0 | 2 |
| Week 169: Level-1 | 1 |
| Week 169: Level-2 | 2 |
| Week 169: Level-3 | 3 |
| Week 169: Level-5 | 2 |
| Week 181: Level-1 | 1 |
| SC/ED: Level-0 | 8 |
| SC/ED: Level-1 | 4 |
| SC/ED: Level-2 | 2 |
| SC/ED: Level-3 | 2 |
| SC/ED: Level-4 | 3 |
| SC/ED: Level-5 | 1 |
| SC/ED: Level-6 | 4 |
| SC/ED: Level-8 | 2 |
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, daily activity RP and impact has 38 items with each item scored on 3 or 4 points ordinal scale. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicating higher perceived risk of having a bleed while doing daily activities and higher impact of hemophilia on daily activities.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 7.50 ± 8.89 |
| RP: Change at Week 13 | -4.11 ± 7.71 |
| RP: Change at Week 25 | -3.93 ± 8.10 |
| RP: Change at Week 37 | -3.76 ± 11.99 |
| RP: Change at Week 49 | -3.04 ± 11.60 |
| RP: Change at Week 61 | -1.79 ± 11.96 |
| RP: Change at Week 73 | -3.77 ± 12.46 |
| RP: Change at Week 85 | -2.58 ± 10.59 |
| RP: Change at Week 97 | -2.26 ± 11.56 |
| RP: Change at Week 109 | 0.79 ± 12.88 |
| RP: Change at Week 121 | -0.56 ± 14.74 |
| RP: Change at Week 133 | -2.46 ± 13.09 |
| RP: Change at Week 145 | 3.57 ± 16.47 |
| RP: Change at Week 157 | -5.10 ± 8.95 |
| RP: Change at Week 169 | -9.52 ± 5.46 |
| RP: Change at SC/ED | -0.22 ± 13.83 |
| Impact: Baseline | 6.01 ± 12.94 |
| Impact: Change at Week 13 | -2.48 ± 10.19 |
| Impact: Change at Week 25 | -1.18 ± 9.03 |
| Impact: Change at Week 37 | -2.11 ± 16.58 |
| Impact: Change at Week 49 | 0.24 ± 13.35 |
| Impact: Change at Week 61 | -0.23 ± 12.92 |
| Impact: Change at Week 73 | -0.26 ± 13.14 |
| Impact: Change at Week 85 | -1.18 ± 11.30 |
| Impact: Change at Week 97 | -0.50 ± 11.98 |
| Impact: Change at Week 109 | 0 ± 13.01 |
| Impact: Change at Week 121 | 0.62 ± 12.70 |
| Impact: Change at Week 133 | -0.59 ± 13.70 |
| Impact: Change at Week 145 | 2.36 ± 14.94 |
| Impact: Change at Week 157 | -5.72 ± 9.22 |
| Impact: Change at Week 169 | -6.29 ± 8.92 |
| Impact: Change at SC/ED | 2.80 ± 13.12 |
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, social activity RP and impact has 16 items which were scored on 3 or 4 points ordinal scale. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher perceived risk of having a bleed while doing social activities and higher impact of hemophilia on social activities.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 16.79 ± 15.76 |
| RP: Change at Week 13 | -5.36 ± 12.45 |
| RP: Change at Week 25 | -4.64 ± 14.15 |
| RP: Change at Week 37 | -4.51 ± 16.87 |
| RP: Change at Week 49 | -4.29 ± 16.29 |
| RP: Change at Week 61 | -3.93 ± 15.63 |
| RP: Change at Week 73 | -7.94 ± 17.65 |
| RP: Change at Week 85 | -7.94 ± 19.58 |
| RP: Change at Week 97 | -5.26 ± 18.42 |
| RP: Change at Week 109 | -5.16 ± 21.75 |
| RP: Change at Week 121 | -3.38 ± 19.10 |
| RP: Change at Week 133 | -5.36 ± 21.59 |
| RP: Change at Week 145 | -2.98 ± 20.31 |
| RP: Change at Week 157 | -5.10 ± 8.95 |
| RP: Change at Week 169 | -4.76 ± 8.25 |
| RP: Change at SC/DV | -6.25 ± 19.67 |
| Impact: Baseline | 7.07 ± 8.45 |
| Impact: Change at Week 13 | -0.70 ± 7.70 |
| Impact: Change at Week 25 | -0.94 ± 8.04 |
| Impact: Change at Week 37 | 0.76 ± 12.82 |
| Impact: Change at Week 49 | 1.19 ± 13.44 |
| Impact: Change at Week 61 | 0.01 ± 11.87 |
| Impact: Change at Week 73 | 1.06 ± 15.48 |
| Impact: Change at Week 85 | 1.07 ± 15.62 |
| Impact: Change at Week 97 | 3.24 ± 15.51 |
| Impact: Change at Week 109 | 0.53 ± 14.91 |
| Impact: Change at Week 121 | 3.25 ± 17.21 |
| Impact: Change at Week 133 | 0.29 ± 16.01 |
| Impact: Change at Week 145 | 0.79 ± 15.15 |
| Impact: Change at Week 157 | -1.35 ± 10.44 |
| Impact: Change at Week 169 | -6.29 ± 7.20 |
| Impact: Change at SC/DV | 2.06 ± 14.50 |
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, recreational activity RP \& impact has 34 items + larger bank of additional items. The items were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher perceived risk of having a bleed while doing recreational activities and higher impact of hemophilia on recreational activities.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 41.57 ± 29.94 |
| RP: Change at Week 13 | -11.17 ± 23.16 |
| RP: Change at Week 25 | -7.47 ± 24.89 |
| RP: Change at Week 37 | -14.15 ± 32.78 |
| RP: Change at Week 49 | -9.34 ± 28.14 |
| RP: Change at Week 61 | -13.53 ± 29.67 |
| RP: Change at Week 73 | -17.14 ± 30.77 |
| RP: Change at Week 85 | -14.09 ± 29.91 |
| RP: Change at Week 97 | -12.47 ± 33.00 |
| RP: Change at Week 109 | -15.95 ± 33.99 |
| RP: Change at Week 121 | -12.75 ± 35.83 |
| RP: Change at Week 133 | -11.23 ± 34.77 |
| RP: Change at Week 145 | -12.34 ± 35.96 |
| RP: Change at Week 157 | 0.73 ± 9.57 |
| RP: Change at Week 169 | 2.08 ± 3.61 |
| RP: Change at SC/ED | -13.32 ± 34.32 |
| Impact: Baseline | 14.51 ± 14.70 |
| Impact: Change at Week 13 | 3.75 ± 16.90 |
| Impact: Change at Week 25 | 3.07 ± 15.32 |
| Impact: Change at Week 37 | -0.38 ± 25.40 |
| Impact: Change at Week 49 | -0.50 ± 20.97 |
| Impact: Change at Week 61 | -1.41 ± 19.66 |
| Impact: Change at Week 73 | -5.04 ± 18.33 |
| Impact: Change at Week 85 | 2.86 ± 19.71 |
| Impact: Change at Week 97 | 4.89 ± 24.38 |
| Impact: Change at Week 109 | 0.33 ± 21.54 |
| Impact: Change at Week 121 | 0.93 ± 26.46 |
| Impact: Change at Week 133 | 3.58 ± 27.64 |
| Impact: Change at Week 145 | -1.92 ± 14.97 |
| Impact: Change at Week 157 | -1.75 ± 10.66 |
| Impact: Change at Week 169 | -8.25 ± 14.29 |
| Impact: Change at SC/ED | 4.17 ± 19.76 |
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, school impact has 11 items and the items were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher impact of hemophilia on school activities.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 12.86 ± 8.45 |
| Change at Week 13 | -1.29 ± 6.99 |
| Change at Week 25 | -0.71 ± 16.49 |
| Change at Week 37 | 3.32 ± 13.07 |
| Change at Week 49 | -0.17 ± 7.91 |
| Change at Week 61 | 0.99 ± 12.02 |
| Change at Week 73 | 4.92 ± 22.04 |
| Change at Week 85 | -0.19 ± 10.28 |
| Change at Week 97 | 4.62 ± 19.21 |
| Change at Week 109 | 0.39 ± 10.45 |
| Change at Week 121 | -0.18 ± 11.64 |
| Change at Week 133 | 0.22 ± 11.68 |
| Change at Week 145 | 8.47 ± 24.48 |
| Change at Week 157 | -4.71 ± 8.27 |
| Change at Week 169 | -7.67 ± 6.93 |
| Change at SC/ED | 1.41 ± 8.68 |
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, preoccupation has 3 items which were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 47.98 ± 25.81 |
| Change at Week 13 | -2.38 ± 40.16 |
| Change at Week 25 | -7.43 ± 30.68 |
| Change at Week 37 | -6.18 ± 26.73 |
| Change at Week 49 | -10.75 ± 31.03 |
| Change at Week 61 | -9.10 ± 27.77 |
| Change at Week 73 | -3.58 ± 30.98 |
| Change at Week 85 | -11.89 ± 28.42 |
| Change at Week 97 | -15.66 ± 33.94 |
| Change at Week 109 | -11.03 ± 26.79 |
| Change at Week 121 | -18.26 ± 29.27 |
| Change at Week 133 | -19.66 ± 29.92 |
| Change at Week 145 | -20.71 ± 32.67 |
| Change at Week 157 | -25.93 ± 38.41 |
| Change at Week 169 | -11.00 ± 9.53 |
| Change at SC/ED | -8.16 ± 31.05 |
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, treatment burden has 7 items which were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated lower perceived burden of the hemophilia treatment.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 38.91 ± 27.98 |
| Change at Week 13 | 13.30 ± 26.72 |
| Change at Week 25 | 18.29 ± 26.56 |
| Change at Week 37 | 16.25 ± 30.54 |
| Change at Week 49 | 9.67 ± 29.57 |
| Change at Week 61 | 14.13 ± 30.50 |
| Change at Week 73 | 15.95 ± 30.08 |
| Change at Week 85 | 21.54 ± 33.68 |
| Change at Week 97 | 18.64 ± 32.00 |
| Change at Week 109 | 16.62 ± 33.45 |
| Change at Week 121 | 19.25 ± 35.00 |
| Change at Week 133 | 15.92 ± 30.53 |
| Change at Week 145 | 9.71 ± 30.57 |
| Change at Week 157 | 18.21 ± 26.17 |
| Change at Week 169 | 1.83 ± 16.17 |
| Change at SC/ED | 16.63 ± 36.63 |
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, pain domain (Hurt) consists of two items, assessed using an 11-point numeric rating scale where 0 = no hurt and 10 = a lot of hurt. The data reported here are from participants who answered the following question "Did you get a bleed in the past 7 days? ( If yes, how much did the bleed hurt?)." Data is reported only for categories/timepoints with non-zero values.
| Participants | Emicizumab |
|---|---|
| Baseline: Level-4 | 1 |
| Baseline: Level-5 | 1 |
| Baseline: Level-9 | 1 |
| Week 13: Level-1 | 1 |
| Week 25: Level-6 | 1 |
| Week 37: Level-3 | 1 |
| Week 49: Level-6 | 1 |
| Week 61: Level-7 | 1 |
| Week 61: Level-8 | 1 |
| Week 85: Level-1 | 1 |
| Week 97: Level-0 | 1 |
| Week 97: Level-3 | 1 |
| Week 109: Level-1 | 2 |
| Week 109: Level-4 | 2 |
| Week 121: Level-6 | 1 |
| Week 121: Level-8 | 1 |
| Week 133: Level-2 | 1 |
| Week 145: Level-7 | 1 |
| Week 157: Level-5 | 1 |
CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, pain domain (Hurt) consists of two items, assessed using an 11-point numeric rating scale where 0 = no hurt and 10 = a lot of hurt. The data reported here are from participants who answered the following question "What is the WORST that your body has hurt over the past 7 days". Data is reported only for categories/timepoints with non-zero values.
| Participants | Emicizumab |
|---|---|
| Baseline: Level-0 | 3 |
| Baseline: Level-1 | 5 |
| Baseline: Level-2 | 3 |
| Baseline: Level-3 | 2 |
| Baseline: Level-4 | 1 |
| Baseline: Level-5 | 2 |
| Baseline: Level-7 | 1 |
| Baseline: Level-8 | 1 |
| Baseline: Level-9 | 1 |
| Week 13: Level-0 | 9 |
| Week 13: Level-1 | 3 |
| Week 13: Level-2 | 2 |
| Week 13: Level-3 | 2 |
| Week 13: Level-4 | 1 |
| Week 13: Level-8 | 1 |
| Week 13: Level-9 | 1 |
| Week 25: Level-0 | 8 |
| Week 25: Level-1 | 1 |
| Week 25: Level-2 | 4 |
| Week 25: Level-3 | 2 |
| Week 25: Level-5 | 2 |
| Week 25: Level-6 | 2 |
| Week 37: Level-0 | 3 |
| Week 37: Level-1 | 4 |
| Week 37: Level-2 | 3 |
| Week 37: Level-3 | 5 |
| Week 37: Level-4 | 2 |
| Week 37: Level-6 | 1 |
| Week 49: Level-0 | 5 |
| Week 49: Level-1 | 2 |
| Week 49: Level-2 | 4 |
| Week 49: Level-3 | 1 |
| Week 49: Level-4 | 2 |
| Week 49: Level-5 | 3 |
| Week 49: Level-7 | 1 |
| Week 49: Level-8 | 1 |
| Week 61: Level-0 | 6 |
| Week 61: Level-1 | 1 |
| Week 61: Level-2 | 1 |
| Week 61: Level-3 | 2 |
| Week 61: Level-4 | 3 |
| Week 61: Level-5 | 1 |
| Week 61: Level-6 | 2 |
| Week 61: Level-7 | 2 |
| Week 61: Level-8 | 1 |
| Week 61: Level-9 | 1 |
| Week 73: Level-0 | 4 |
| Week 73: Level-1 | 2 |
| Week 73: Level-2 | 3 |
| Week 73: Level-3 | 2 |
| Week 73: Level-4 | 2 |
| Week 73: Level-6 | 4 |
| Week 73: Level-7 | 1 |
| Week 85: Level-0 | 4 |
| Week 85: Level-1 | 3 |
| Week 85: Level-2 | 1 |
| Week 85: Level-3 | 2 |
| Week 85: Level-4 | 2 |
| Week 85: Level-5 | 1 |
| Week 85: Level-6 | 3 |
| Week 85: Level-7 | 1 |
| Week 85: Level-8 | 1 |
| Week 97: Level-0 | 5 |
| Week 97: Level-1 | 2 |
| Week 97: Level-2 | 2 |
| Week 97: Level-3 | 1 |
| Week 97: Level-4 | 1 |
| Week 97: Level-5 | 3 |
| Week 97: Level-6 | 2 |
| Week 97: Level-7 | 3 |
| Week 109: Level-0 | 3 |
| Week 109: Level-1 | 3 |
| Week 109: Level-2 | 3 |
| Week 109: Level-3 | 2 |
| Week 109: Level-4 | 3 |
| Week 109: Level-5 | 2 |
| Week 109: Level-8 | 1 |
| Week 109: Level-10 | 1 |
| Week 121: Level-0 | 3 |
| Week 121: Level-1 | 2 |
| Week 121: Level-2 | 1 |
| Week 121: Level-3 | 2 |
| Week 121: Level-4 | 2 |
| Week 121: Level-5 | 4 |
| Week 121: Level-6 | 3 |
| Week 121: Level-8 | 2 |
| Week 133: Level-0 | 3 |
| Week 133: Level-1 | 1 |
| Week 133: Level-2 | 6 |
| Week 133: Level-4 | 2 |
| Week 133: Level-5 | 2 |
| Week 133: Level-6 | 1 |
| Week 133: Level-10 | 1 |
| Week 145: Level-0 | 2 |
| Week 145: Level-1 | 1 |
| Week 145: Level-2 | 3 |
| Week 145: Level-3 | 1 |
| Week 145: Level-5 | 3 |
| Week 145: Level-8 | 1 |
| Week 145: Level-10 | 1 |
| Week 157: Level-0 | 3 |
| Week 157: Level-2 | 1 |
| Week 157: Level-3 | 1 |
| Week 157: Level-4 | 1 |
| Week 157: Level-5 | 1 |
| Week 169: Level-0 | 1 |
| Week 169: Level-1 | 1 |
| Week 169: Level-3 | 1 |
| SC/ED: Level-0 | 3 |
| SC/ED: Level-1 | 1 |
| SC/ED: Level-2 | 5 |
| SC/ED: Level-5 | 2 |
| SC/ED: Level-6 | 3 |
| SC/ED: Level-8 | 2 |
CATCH was used to measure the effect of hemophilia and its treatment on caregivers of pediatric participants (aged \<8 years). The caregiver version has 2 domains (preoccupation and treatment burden). Of this, preoccupation has 13 items with each of the items were scored on 4 or 5 ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 53.54 ± 17.84 |
| Change at Week 13 | -6.02 ± 11.48 |
| Change at Week 25 | -9.95 ± 10.09 |
| Change at Week 37 | -10.00 ± 15.40 |
| Change at Week 49 | -8.75 ± 14.46 |
| Change at Week 61 | -10.42 ± 13.50 |
| Change at Week 73 | -17.71 ± 12.10 |
| Change at Week 85 | -15.28 ± 11.83 |
| Change at Week 97 | -11.72 ± 14.64 |
| Change at Week 109 | -16.46 ± 11.68 |
| Change at Week 121 | -10.21 ± 11.09 |
| Change at Week 133 | -15.89 ± 17.07 |
| Change at Week 145 | -17.59 ± 17.53 |
| Change at Week 157 | -22.50 ± 19.62 |
| Change at Week 169 | -22.92 ± 7.51 |
| Change at SC/ED | -15.42 ± 18.67 |
CATCH was used to measure the effect of hemophilia and its treatment on caregivers of pediatric participants (aged \<8 years). The caregiver version has 2 domains (preoccupation and treatment burden). Of this, treatment burden has 8 items which were scored on 4 or 5 ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater perceived burden of the hemophilia treatment.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 43.93 ± 21.50 |
| Change at Week 13 | -13.49 ± 16.34 |
| Change at Week 25 | -18.65 ± 16.44 |
| Change at Week 37 | -20.00 ± 14.79 |
| Change at Week 49 | -19.64 ± 19.65 |
| Change at Week 61 | -28.97 ± 15.51 |
| Change at Week 73 | -26.79 ± 19.75 |
| Change at Week 85 | -28.17 ± 19.27 |
| Change at Week 97 | -21.88 ± 20.24 |
| Change at Week 109 | -22.14 ± 24.44 |
| Change at Week 121 | -21.43 ± 28.22 |
| Change at Week 133 | -23.66 ± 16.85 |
| Change at Week 145 | -22.62 ± 18.90 |
| Change at Week 157 | -24.29 ± 14.15 |
| Change at Week 169 | -28.57 ± 18.56 |
| Change at SC/ED | -28.57 ± 23.01 |
The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the participant's preference for treatment with subcutaneous (SC) emicizumab, intravenous (IV) factor VIIII (FVIII), or no preference. The 95% confidence intervals were calculated using the Pearson-Clopper method.
| Percentage of participants | Emicizumab |
|---|---|
| Prefer the New Study Drug Treatment (Emicizumab SC) | 96.2 (86.79 to 99.53) |
| Prefer My Old Hemophilia Treatment (IV) | 1.9 (0.05 to 10.26) |
| Have No Preference | 1.9 (0.05 to 10.26) |
The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the caregiver's preference for their child's treatment with subcutaneous (SC) emicizumab, intravenous (IV) factor VIIII (FVIII), or no preference. The 95% confidence intervals were calculated using the Pearson-Clopper method.
| Percentage of caregivers | Emicizumab |
|---|---|
| Prefer the New Study Drug Treatment (Emicizumab SC) | 85.7 (67.33 to 95.97) |
| Prefer My Child's Old Hemophilia Treatment (IV) | 3.6 (0.09 to 18.35) |
| Have No Preference | 10.7 (2.27 to 28.23) |
The HJHS measures joint health of the joints (knees, ankles, and elbows) most commonly affected by bleeding in hemophilia. The HJHS 2.1 provides joint specific total scores which are added to obtain the sum of joints totals and also a global gait score. These two scores are then added to obtain HJHS total score. The minimum score per joint is 0, the maximum score is 20. In addition, Gait is scored on a scale from 0 to 4 based on the number of skills that are not within the normal limits. The total score is the sum of scores across all six joints plus the gait score (range from 0 to 124, with 0 being normal and 124 being the most severe disease). A higher score indicates worse joint health.
| score on a scale | Emicizumab |
|---|---|
| Baseline | 7.57 ± 10.51 |
| Change at Week 25 | -1.20 ± 3.10 |
| Change at Week 29 | 0 ± 0 |
| Change at Week 49 | -1.31 ± 3.65 |
| Change at Week 73 | -1.15 ± 4.02 |
| Change at Week 97 | -1.40 ± 3.33 |
| Change at Week 121 | -0.96 ± 3.61 |
| Change at Week 145 | -2.00 ± 3.68 |
| Change at Week 169 | -2.50 ± 4.45 |
| Change at SC/ED | 1.42 ± 3.95 |
For physical activity assessment, participants ≥5 years of age were instructed to wear the study accelerometry device on the wrist continuously (24 hours/day) every day for the designated 2-week periods during the study. A participant was considered to be compliant with the physical activity assessments if they wore the study device continuously (≥8 hours/day) every day for at least 8 days of each of the designated 2-week periods during the study. If this compliance criterion was not reached at a specific timepoint the participant was not included in the analysis of the designated 2-week periods where compliance was not reached. Daily measurements were averaged over the 14-days timepoint. Activity count was a measure of the acceleration measured by the device. The daily peak activity duration was defined as the sum of moderate to vigorous activity per day (in minutes).
| Minutes per day | Participants ≥5 Years Old: Emicizumab | Participants ≥5 to <18 Years Old: Emicizumab | Participants ≥18 Years Old: Emicizumab |
|---|---|---|---|
| Baseline (BL) - Value at Visit | 130 ± 56 | 168 ± 66 | 108 ± 35 |
| Change from BL at Week 13 | -2 ± 34 | -4 ± 42 | -1 ± 29 |
| Change from BL at Week 25 | 4 ± 53 | -4 ± 74 | 8 ± 37 |
| Change from BL at Week 37 | 14 ± 55 | 17 ± 73 | 12 ± 40 |
| Change from BL at Week 49 | 17 ± 40 | 19 ± 51 | 16 ± 34 |
For physical activity assessment, participants ≥5 years of age were instructed to wear the study accelerometry device on the wrist continuously (24 hours/day) every day for the designated 2-week periods during the study. A participant was considered to be compliant with the physical activity assessments if they wore the study device continuously (≥8 hours/day) every day for at least 8 days of each of the designated 2-week periods during the study. If this compliance criterion was not reached at a specific timepoint the participant was not included in the analysis of the designated 2-week periods where compliance was not reached. Daily measurements were averaged over the 14-days timepoint. Activity count was a measure of the acceleration measured by the device.
| Step count per day | Participants ≥5 Years Old: Emicizumab | Participants ≥5 to <18 Years Old: Emicizumab | Participants ≥18 Years Old: Emicizumab |
|---|---|---|---|
| Baseline (BL) - Value at Visit | 6441 ± 2617 | 6755 ± 3168 | 6263 ± 2276 |
| Change from BL at Week 13 | 44 ± 1846 | -18 ± 2361 | 87 ± 1423 |
| Change from BL at Week 25 | 119 ± 2977 | -69 ± 4348 | 225 ± 1901 |
| Change from BL at Week 37 | 767 ± 3189 | 1403 ± 4544 | 356 ± 1852 |
| Change from BL at Week 49 | 1216 ± 2440 | 1740 ± 3130 | 919 ± 1945 |
The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The MBQ score ranges from 0 to 75. Higher scores indicate a worse quality of life and more severe symptoms.
| score on scale | Emicizumab |
|---|---|
| Baseline | 26.00 ± 8.49 |
| Change at Week 5 | -13.50 ± 20.51 |
| Change at Week 9 | -12.50 ± 9.19 |
| Change at Week 13 | -12.00 ± 5.66 |
| Change at Week 17 | -12.00 ± 12.73 |
| Change at Week 21 | -15.00 ± 12.73 |
| Change at Week 25 | -13.50 ± 9.19 |
| Change at Week 29 | -10.50 ± 7.78 |
| Change at Week 33 | -18.50 ± 10.61 |
| Change at Week 37 | -17.00 ± 8.49 |
| Change at Week 41 | -13.50 ± 9.19 |
| Change at Week 45 | -15.00 ± 11.31 |
| Change at Week 49 | -21.00 ± NA |
| Change at Week 53 (n=1) | -20.00 ± NA |
| Change at Week 57 | -21.00 ± NA |
| Change at Week 61 | -17.50 ± 10.61 |
| Change at Week 65 | -17.50 ± 6.36 |
| Change at Week 69 | -16.00 ± 9.90 |
| Change at Week 73 | -15.50 ± 10.61 |
| Change at Week 77 | -8.00 ± NA |
| Change at Week 81 | -9.00 ± NA |
| Change at Week 85 | -10.00 ± NA |
| Change at Week 89 | -7.00 ± NA |
| Change at Week 93 | -6.00 ± NA |
| Change at Week 97 | -11.00 ± NA |
| Change at Week 101 | -8.00 ± NA |
| Change at Week 104 | -8.00 ± NA |
| Change at Week 109 | -10.00 ± NA |
| Change at Week 113 | -9.00 ± NA |
| Change at Week 117 | -9.00 ± NA |
| Change at Week 121 | -9.00 ± NA |
| Change at Week 125 | -9.00 ± NA |
| Change at Week 129 | -11.00 ± NA |
| Change at Week 133 | -9.00 ± NA |
| Change at Week 137 | -11.00 ± NA |
| Change at Week 141 | -13.00 ± NA |
| Change at Week 145 | -13.00 ± NA |
The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for heaviness subscale ranges from 0 to 29. Higher score indicates more heavy bleeding.
| score on scale | Emicizumab |
|---|---|
| Baseline | 9.50 ± 4.95 |
| Change at Week 5 | -1.00 ± NA |
| Change at Week 9 | -5.50 ± 3.54 |
| Change at Week 13 | -4.50 ± 2.12 |
| Change at Week 17 | -5.00 ± 5.66 |
| Change at Week 21 | -7.50 ± 4.95 |
| Change at Week 25 | -4.00 ± NA |
| Change at Week 29 | -5.50 ± 3.54 |
| Change at Week 33 | -9.00 ± 4.24 |
| Change at Week 37 | -9.00 ± 4.24 |
| Change at Week 41 | -4.00 ± NA |
| Change at Week 45 | -7.00 ± 7.07 |
| Change at Week 49 | -11.00 ± NA |
| Change at Week 53 | -9.00 ± NA |
| Change at Week 57 | -10.00 ± NA |
| Change at Week 61 | -5.00 ± NA |
| Change at Week 65 | -11.00 ± NA |
| Change at Week 69 | -8.50 ± 4.95 |
| Change at Week 73 | -7.50 ± 6.36 |
| Change at Week 77 | -4.00 ± NA |
| Change at Week 81 | -5.00 ± NA |
| Change at Week 89 | -3.00 ± NA |
| Change at Week 93 | -3.00 ± NA |
| Change at Week 97 | -5.00 ± NA |
| Change at Week 101 | -4.00 ± NA |
| Change at Week 104 | -4.00 ± NA |
| Change at Week 109 | -5.00 ± NA |
| Change at Week 113 | -5.00 ± NA |
| Change at Week 121 | -5.00 ± NA |
| Change at Week 125 | -5.00 ± NA |
| Change at Week 129 | -6.00 ± NA |
| Change at Week 133 | -5.00 ± NA |
| Change at Week 137 | -5.00 ± NA |
The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for QoL subscale ranges from 0 to 37. Higher scores indicate a worse QoL.
| score on scale | Emicizumab |
|---|---|
| Baseline | 11.00 ± 2.83 |
| Change at Week 5 | -5.50 ± 10.61 |
| Change at Week 9 | -5.50 ± 7.78 |
| Change at Week 13 | -5.00 ± 5.66 |
| Change at Week 17 | -5.00 ± 7.07 |
| Change at Week 21 | -6.00 ± 9.90 |
| Change at Week 25 | -3.00 ± 4.24 |
| Change at Week 29 | -3.50 ± 4.95 |
| Change at Week 33 | -6.00 ± 5.66 |
| Change at Week 37 | -6.00 ± 5.66 |
| Change at Week 41 | -3.00 ± 4.24 |
| Change at Week 45 | -5.50 ± 4.95 |
| Change at Week 49 | -9.00 ± NA |
| Change at Week 53 | -10.00 ± NA |
| Change at Week 57 | -10.00 ± NA |
| Change at Week 61 | -6.00 ± 5.66 |
| Change at Week 65 | -6.50 ± 4.95 |
| Change at Week 69 | -6.00 ± 5.66 |
| Change at Week 73 | -6.00 ± 5.66 |
| Change at Week 77 | -2.00 ± NA |
| Change at Week 81 | -2.00 ± NA |
| Change at Week 85 | -3.00 ± NA |
| Change at Week 89 | -3.00 ± NA |
| Change at Week 93 | -2.00 ± NA |
| Change at Week 97 | -4.00 ± NA |
| Change at Week 101 | -3.00 ± NA |
| Change at Week 104 | -3.00 ± NA |
| Change at Week 109 | -3.00 ± NA |
| Change at Week 113 | -3.00 ± NA |
| Change at Week 121 | -3.00 ± NA |
| Change at Week 125 | -3.00 ± NA |
| Change at Week 129 | -3.00 ± NA |
| Change at Week 133 | -3.00 ± NA |
| Change at Week 137 | -4.00 ± NA |
| Change at Week 141 | -4.00 ± NA |
| Change at Week 145 | -4.00 ± NA |
The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for irregularity subscale ranges from 0 to 6. Higher score indicates more irregularity.
| score on scale | Emicizumab |
|---|---|
| Baseline | 4.00 ± 1.41 |
| Change at Week 5 | 0 ± 1.41 |
| Change at Week 9 | -0.50 ± 0.71 |
| Change at Week 13 | -1.50 ± 0.71 |
| Change at Week 17 | -1.50 ± 0.71 |
| Change at Week 21 | -1.00 ± 0 |
| Change at Week 25 | -0.50 ± 0.71 |
| Change at Week 29 | -0.50 ± 0.71 |
| Change at Week 33 | -2.50 ± 2.12 |
| Change at Week 37 | -1.50 ± 0.71 |
| Change at Week 41 | -0.50 ± 0.71 |
| Change at Week 45 | -1.50 ± 0.71 |
| Change at Week 49 | -1.00 ± NA |
| Change at Week 53 | -1.00 ± NA |
| Change at Week 57 | -1.00 ± NA |
| Change at Week 61 | -1.00 ± 0 |
| Change at Week 65 | -1.50 ± 0.71 |
| Change at Week 69 | -0.50 ± 0.71 |
| Change at Week 73 | -1.00 ± 0 |
| Change at Week 85 | 1.00 ± NA |
| Change at Week 93 | 0 ± NA |
| Change at Week 97 | 0 ± NA |
| Change at Week 101 | 0 ± NA |
| Change at Week 104 | 0 ± NA |
| Change at Week 113 | 0 ± NA |
| Change at Week 117 | 0 ± NA |
| Change at Week 121 | 0 ± NA |
| Change at Week 125 | 0 ± NA |
| Change at Week 129 | 0 ± NA |
| Change at Week 133 | 0 ± NA |
| Change at Week 137 | 0 ± NA |
| Change at Week 141 | -1.00 ± NA |
| Change at Week 145 | -1.00 ± NA |
The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for pain subscale ranges from 0 to 3. Higher score indicates severe pain.
| score on scale | Emicizumab |
|---|---|
| Baseline | 1.50 ± 0.71 |
| Change at Week 5 | -1.00 ± NA |
| Change at Week 9 | -1.00 ± 1.41 |
| Change at Week 13 | -1.00 ± 1.41 |
| Change at Week 17 | -0.50 ± 0.71 |
| Change at Week 21 | -0.50 ± 2.12 |
| Change at Week 25 | -2.00 ± NA |
| Change at Week 29 | -1.00 ± 1.41 |
| Change at Week 33 | -1.00 ± 1.41 |
| Change at Week 37 | -0.50 ± 2.12 |
| Change at Week 41 | -2.00 ± NA |
| Change at Week 45 | -1.00 ± 1.41 |
| Change at Week 49 | 0 ± NA |
| Change at Week 53 | 0 ± NA |
| Change at Week 57 | 0 ± NA |
| Change at Week 61 | -2.00 ± NA |
| Change at Week 65 | 0 ± NA |
| Change at Week 69 | -1.00 ± 1.41 |
| Change at Week 73 | -1.00 ± 1.41 |
| Change at Week 77 | -2.00 ± NA |
| Change at Week 81 | -2.00 ± NA |
| Change at Week 89 | -1.00 ± NA |
| Change at Week 93 | -1.00 ± NA |
| Change at Week 97 | -2.00 ± NA |
| Change at Week 101 | -1.00 ± NA |
| Change at Week 104 | -1.00 ± NA |
| Change at Week 109 | -2.00 ± NA |
| Change at Week 113 | -1.00 ± NA |
| Change at Week 121 | -1.00 ± NA |
| Change at Week 125 | -1.00 ± NA |
| Change at Week 129 | -2.00 ± NA |
| Change at Week 133 | -1.00 ± NA |
| Change at Week 137 | -2.00 ± NA |
The Menstruation Diary used a PBAC, which has shown good correlation with menstrual blood loss. The PBAC is a chart that records the occurrence and size of clots, and the number of episodes of heavy bleeding (flooding), as well as depicts the amount of blood loss during a cycle.The PBAC records pad and tampon use (as either light \[1 point\], medium \[5 points\], or heavy \[10 points\] flow), clots (small \[1 point\] or large \[5 points\]), and flooding episodes (1 point each) which can be recorded as many times as necessary any day of the month. The PBAC is scored from 0 (no bleeding) onwards, with a score of \>100 defining abnormal coagulation and heavy menstrual bleeding (corresponds to \>80ml of blood loss per menstrual cycle).
| score on scale | Emicizumab |
|---|---|
| Month 1 | 141.67 ± 140.69 |
| Month 2 | 134.00 ± 47.57 |
| Month 3 | 126.33 ± 41.67 |
| Month 4 | 71.00 ± 49.43 |
| Month 5 | 103.33 ± 107.74 |
| Month 6 | 127.00 ± 77.12 |
| Month 7 | 104.50 ± 2.12 |
| Month 8 | 73.67 ± 53.93 |
| Month 9 | 49.67 ± 27.68 |
| Month 10 | 58.00 ± 42.93 |
| Month 11 | 36.00 ± 23.90 |
| Month 12 | 71.00 ± 43.41 |
| Month 13 | 67.67 ± 42.85 |
| Month 14 | 77.00 ± 36.77 |
| Month 15 | 27.67 ± 35.73 |
| Month 16 | 98.00 ± 32.53 |
| Month 17 | 101.67 ± 36.25 |
| Month 18 | 97.00 ± 42.43 |
| Month 19 | 56.00 ± 79.20 |
| Month 20 | 52.50 ± 14.85 |
| Month 21 | 90.50 ± 20.51 |
| Month 22 | 57.00 ± 15.56 |
| Month 23 | 109.50 ± 62.93 |
| Month 24 | 59.50 ± 26.16 |
| Month 25 | 100.00 ± 32.53 |
| Month 26 | 72.50 ± 74.25 |
| Month 27 | 4.50 ± 6.36 |
| Month 28 | 69.50 ± 64.35 |
| Month 29 | 60.00 ± 26.87 |
| Month 30 | 51.00 ± NA |
| Month 31 | 93.50 ± 57.28 |
| Month 32 | 79.50 ± 0.71 |
| Month 33 | 16.50 ± 20.51 |
| Month 34 | 77.50 ± 53.03 |
| Month 36 | 74.50 ± 71.42 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. As per WHO toxicity grading, Grade 1= mild, 2= moderate, 3=severe, 4=life threatening.
| Participants | Emicizumab |
|---|---|
| Grade-1 | 20 |
| Grade-2 | 38 |
| Grade-3 | 7 |
| Grade-4 | 2 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
| Participants | Emicizumab |
|---|---|
| Number of Participants With Adverse Events Leading to Study Drug Discontinuation | 0 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. The following signs and symptoms were recognized as potential thromboembolism (i.e., dyspnea, chest pain, leg pain, or swelling; or if in the head, headache, numbness in the face, eye pain or swelling, or vision impairment).
| Participants | Emicizumab |
|---|---|
| Number of Participants With at Least One Thromboembolic Event | 2 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. TMA is used to describe a group of disorders with clinical features of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage that can include the kidneys, gastrointestinal system, central nervous system, etc.
| Participants | Emicizumab |
|---|---|
| Number of Participants With at Least One Event of Thrombotic Microangiopathy | 0 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Injection-site reactions are defined as AEs related that occur within 24 hours after study drug administration and are judged to be related to the study drug injection. Local injection-site reactions included erythema, hematoma, rash, discomfort, pain, and pruritus and were mostly of mild and moderate intensity. As per WHO toxicity grading, Grade 1= mild, 2= moderate, 3=severe, 4=life threatening.
| Participants | Emicizumab |
|---|---|
| Grade-1 | 13 |
| Grade-2 | 0 |
| Grade-3 | 0 |
| Grade-4 | 0 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
| Participants | Emicizumab |
|---|---|
| Number of Participants With at Least One Severe Hypersensitivity, Anaphylaxis, and Anaphylactoid Event | 0 |
An abnormal laboratory value was defined as a laboratory test result outside of the normal range for hematology or serum chemistry parameters. The WHO toxicity grading scale, which ranges from Grades 1 to 4 (least severe to most severe, respectively; Grade 0 is within normal range), was used for assessing the severity of laboratory abnormalities and adverse events (WHO 2003). Not every laboratory abnormality qualified as an adverse event; an abnormality was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
| Participants | Emicizumab |
|---|---|
| Calcium (Low): Grade 0 (Baseline) to Grade4 (PB) | 1 |
| Glucose (High): Grade1 (Baseline) to Grade 3 (PB) | 2 |
| Phosphorus (low):Grade 0 (Baseline) to Grade 3 (PB) | 2 |
| Phosphorus (low): Grade0 (Baseline) to Grade 4(PB) | 1 |
| Potassium(high):Grade0 (Baseline) to Grade 3(PB) | 2 |
| Potassium(high): Grade0 (Baseline) toGrade4(PB) | 1 |
| AST(high): Grade0 (Baseline to Grade 3(PB) | 2 |
The number of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. All of the adverse events reported here were assessed independently by the investigator as not related to treatment with emicizumab.
| Participants | Emicizumab |
|---|---|
| Pyrexia | 4 |
| Hypertension | 1 |
| milliseconds | Emicizumab |
|---|---|
| QT: Baseline | 387.6 ± 34.3 |
| QT: Change at Week 5 | -2.7 ± 21.1 |
| QT: Change at Week 25 | 0.8 ± 25.7 |
| QT: Change at Week 49 | 4.3 ± 25.1 |
| QT: Change at Week 61 | -2.8 ± 21.5 |
| QT: Change at Week 73 | -2.2 ± 26.8 |
| QT: Change at Week 85 | -1.0 ± 26.1 |
| QT: Change at Week 97 | 3.2 ± 27.1 |
| QT: Change at Week 109 | 1.0 ± 29.3 |
| QT: Change at Week 121 | 1.9 ± 22.5 |
| QT: Change at Week 133 | 4.4 ± 22.4 |
| QT: Change at Week 145 | 6.4 ± 22.4 |
| QT: Change at Week 157 | 7.6 ± 20.2 |
| QT: Change at Week 169 | 3.9 ± 30.2 |
| QT: Change at Week 181 | 19.8 ± 9.4 |
| QT: Change at SC/ED | 4.1 ± 25.7 |
| PR: Baseline | 146.1 ± 25.6 |
| PR: Change at Week 5 | -1.3 ± 11.4 |
| PR: Change at Week 25 | 1.1 ± 11.6 |
| PR: Change at Week 49 | 1.5 ± 17.3 |
| PR: Change at Week 61 | 1.4 ± 12.1 |
| PR: Change at Week 73 | -0.1 ± 13.0 |
| PR: Change at Week 85 | 1.9 ± 15.6 |
| PR: Change at Week 97 | 1.1 ± 19.7 |
| PR: Change at Week 109 | 5.4 ± 13.4 |
| PR: Change at Week 121 | 2.8 ± 15.3 |
| PR: Change at Week 133 | 4.1 ± 13.7 |
| PR: Change at Week 145 | 6.9 ± 11.5 |
| PR: Change at Week 157 | 7.2 ± 15.1 |
| PR: Change at Week 169 | 7.8 ± 12.9 |
| PR: Change at Week 181 | -2.5 ± 7.0 |
| PR: Change at SC/ED | 3.5 ± 10.9 |
| QRS: Baseline | 89.4 ± 14.4 |
| QRS: Change at Week 5 | 0.6 ± 10.6 |
| QRS: Change at Week 25 | 1.5 ± 11.8 |
| QRS: Change at Week 49 | 1.3 ± 12.7 |
| QRS: Change at Week 61 | 0.5 ± 13.0 |
| QRS: Change at Week 73 | 0.8 ± 13.8 |
| QRS: Change at Week 85 | 0.9 ± 15.1 |
| QRS: Change at Week 97 | 2.6 ± 14.7 |
| QRS: Change at Week 109 | 1.4 ± 13.7 |
| QRS: Change at Week 121 | 0.3 ± 15.0 |
| QRS: Change at Week 133 | 2.5 ± 12.9 |
| QRS: Change at Week 145 | 2.2 ± 11.0 |
| QRS: Change at Week 157 | 2.3 ± 12.9 |
| QRS: Change at Week 169 | 2.1 ± 13.2 |
| QRS: Change at Week 181 | 3.3 ± 29.1 |
| QRS: Change at SC/ED | 4.1 ± 12.3 |
| beats per minutes | Emicizumab |
|---|---|
| Baseline | 70.2 ± 15.7 |
| Change at Week 5 | -1.2 ± 9.9 |
| Change at Week 25 | -2.5 ± 9.9 |
| Change at Week 49 | -4.2 ± 11.7 |
| Change at Week 61 | -2.2 ± 11.9 |
| Change at Week 73 | -1.3 ± 12.5 |
| Change at Week 85 | -1.4 ± 12.3 |
| Change at Week 97 | -4.5 ± 12.3 |
| Change at Week 109 | -1.7 ± 14.7 |
| Change at Week 121 | -1.9 ± 13.0 |
| Change at Week 133 | -3.9 ± 11.7 |
| Change at Week 145 | -6.7 ± 12.3 |
| Change at Week 157 | -8.1 ± 15.2 |
| Change at Week 169 | -3.3 ± 13.3 |
| Change at Week 181 | -8.8 ± 10.5 |
| Change at SC/ED | -3.9 ± 12.8 |
| micrograms per millilitre (μg/mL) | Emicizumab 1.5 mg/kg QW | Emicizumab 3 mg/kg Q2W | Emicizumab 6 mg/kg Q4W |
|---|---|---|---|
| Week 1 | NA ± NA | NA ± NA | NA ± NA |
| Week 2 | 19.2 ± 20.8 | 20.9 ± 25.4 | 16.7 ± 32.7 |
| Week 3 | 35.3 ± 24.9 | 37.7 ± 20.4 | 31.9 ± 30.6 |
| Week 4 | 48.7 ± 24.4 | 49.1 ± 23.4 | 44.3 ± 34.1 |
| Week 5 | 59.7 ± 20.4 | 60 ± 18 | 56.8 ± 33.4 |
| Week 9 | 58.9 ± 29.1 | 59 ± 22.2 | 50.1 ± 25.3 |
| Week 13 | 59.4 ± 32.6 | 55 ± 31 | 44.9 ± 21.7 |
| Week 17 | 56.6 ± 22.2 | 53.2 ± 27.4 | 48.5 ± 26.2 |
| Week 21 | 56.6 ± 28.6 | 51.8 ± 31.7 | 46.6 ± 21.8 |
| Week 25 | 56.2 ± 30.8 | 51.2 ± 33 | 45.2 ± 21 |
| Week 29 | 54.4 ± 32.7 | 51.2 ± 28 | 45.1 ± 24.4 |
| Week 33 | 56 ± 33.7 | 51 ± 37.8 | 43.9 ± 25.5 |
| Week 37 | 56.9 ± 33.6 | 52.5 ± 30 | 47 ± 26.2 |
| Week 41 | 52.3 ± 27.1 | 51.2 ± 46.1 | 38.2 ± 56.2 |
| Week 45 | 58.7 ± 37.7 | 49.4 ± 36.8 | 45.9 ± 27.1 |
| Week 49 | 55.8 ± 42.5 | 51.8 ± 35.6 | 47.3 ± 33.1 |
| Week 61 | 55.5 ± 47.9 | 51.6 ± 73.3 | 48.9 ± 28.4 |
| Week 73 | 53.6 ± 54.7 | 53.7 ± 41.8 | 48.1 ± 28.8 |
| Week 85 | 54.3 ± 88.3 | 47.5 ± 71.2 | 46.5 ± 24.4 |
| Week 97 | 47.8 ± 80.1 | 37.9 ± 156 | 49.4 ± 21.3 |
| Week 109 | 53.9 ± 29.6 | 36.4 ± 230 | 42.1 ± 31.9 |
| Week 121 | 45.1 ± 67.1 | 41.7 ± 86.1 | 42.3 ± 27 |
| Week 133 | 41.1 ± 116 | 36.4 ± 102 | 43.1 ± 26.2 |
| Week 145 | 42.6 ± 62.4 | 30.1 ± 215 | 48.4 ± 27.5 |
| Week 157 | 57.3 ± 29.5 | 42.5 ± 54.5 | 42.9 ± 11.6 |
| Week 169 | 62.5 ± 55.7 | 52.5 ± 53.8 | 51.1 ± 12.9 |
| Week 181 | — | 57.7 ± 34.8 | — |
Participants were considered to be ADA positive if they were ADA negative at baseline but develop an ADA response following study drug administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response). The sum of all visits has been reported here.
| Participants | Emicizumab |
|---|---|
| Number of Participants With Anti-Drug Antibodies Against Emicizumab at Baseline and Post-Baseline | 2 |
Central laboratory measurement of anti-FVIII inhibitory antibodies (inhibitors) was performed using a Chromogenic Bethesda Assay (CBA). Participants who develop anti-FVIII inhibitors (titer ≥ 0.6 Bethesda units per milliliter \[BU/mL\]) following study drug administration were summarized.
| Participants | Emicizumab |
|---|---|
| Number of Participants Who Develop Anti-FVIII Inhibitors Over Time | 2 |
Collected over From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Emicizumab | 0/72 (0%) | 17/72 (23.6%) | 55/72 (76.4%) |
| Event | Emicizumab |
|---|---|
| Abdominal painGastrointestinal disorders | 1/72 |
| Mallory-Weiss syndromeGastrointestinal disorders | 1/72 |
| COVID-19Infections and infestations | 1/72 |
| DiverticulitisInfections and infestations | 1/72 |
| ErysipelasInfections and infestations | 1/72 |
| ConcussionInjury, poisoning and procedural complications | 1/72 |
| ContusionInjury, poisoning and procedural complications | 1/72 |
| Foreign body in gastrointestinal tractInjury, poisoning and procedural complications | 1/72 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/72 |
| Renal colicRenal and urinary disorders | 1/72 |
| Event | Emicizumab |
|---|---|
| COVID-19Infections and infestations | 23/72 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 16/72 |
| HeadacheNervous system disorders | 14/72 |
| NasopharyngitisInfections and infestations | 14/72 |
| Injection site reactionGeneral disorders | 13/72 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 9/72 |
| FallInjury, poisoning and procedural complications | 9/72 |
| Limb injuryInjury, poisoning and procedural complications | 6/72 |
| Abdominal pain upperGastrointestinal disorders | 5/72 |
| DiarrhoeaGastrointestinal disorders | 5/72 |
The All Participants Population includes all participants who enrolled in the study.
| Age, Continuous(Years) | Emicizumab |
|---|---|
| Mean | 25.9 ± 17.0 |
| Age, Customized(Participants) | Emicizumab |
|---|---|
| 2 to <6 Years Old | 5 |
| 6 to <12 Years Old | 11 |
| 12 to <18 Years Old | 14 |
| 18 to <65 Years Old | 41 |
| ≥65 Years Old | 2 |
| Sex: Female, Male(Participants) | Emicizumab |
|---|---|
| Female | 3 |
| Male | 70 |
| Ethnicity (NIH/OMB)(Participants) | Emicizumab |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 61 |
| Unknown or Not Reported | 10 |
| Race (NIH/OMB)(Participants) | Emicizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 62 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Hemophilia A Severity(Participants) | Emicizumab |
|---|---|
| Mild | 21 |
| Moderate | 52 |
| Emicizumab Maintenance Dosing Regimen Chosen at Enrollment(Participants) | Emicizumab |
|---|---|
| 1.5 mg/kg Once Every Week (QW) | 25 |
| 3 mg/kg Once Every 2 Weeks (Q2W) | 39 |
| 6 mg/kg Once Every 4 Weeks (Q4W) | 8 |
| Not Assigned (Not Treated) | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Feb 2020 to primary completion in Oct 2021, 20 months.
Results were first posted in Dec 2022, 1 year 1 month after primary completion.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 20 months is below that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emicizumab